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Abstract 
Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disease for which the 
pathological mechanism is heterogeneous and a cure has been elusive. Recent developments 
have linked specific proteins found in pathological neuronal cytoplasmic inclusions (NCIs) 
of ALS motor neurons to familial variants of the disease. These proteins, including TAR 
DNA-binding protein of 43 kDa (TDP-43), fused in sarcoma/translocated in liposarcoma 
(FUS), and Rho guanine nucleotide exchange factor (RGNEF) share the common 
characteristic of being RNA-binding proteins that colocalize within NCIs. RGNEF is unique 
however in also possessing RhoA activation capacity, suggesting a role in the cell stress 
response. My thesis confirms this role, and I also observed that the domain responsible for 
RhoA activation is not critical for RGNEF’s protective effects. Altogether, my work further 
supports the hypothesis of a pathological mechanism of dysfunctional stress response in ALS 
motor neurons where cytoprotective proteins are sequestered in NCIs, leading to 
neurodegeneration.   
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Chapter 1  
1 Thesis rationale  
Amyotrophic lateral sclerosis (ALS) is a progressive, incurable neurodegenerative 
disease affecting primarily motor neurons with a relatively uniform world-wide incidence 
rate of approximately 2.2 of 100,000 people (Chio et al., 2013). Typically, the patient 
develops progressive muscle paralysis with death within 3 – 5 years from a loss of 
respiratory function (Rowland & Shneider, 2001). The risk of developing ALS increases 
with age, with a peak age at onset within the 6
th
 decade of life. This means that as the 
baby-boomer population reaches this peak in onset an increasing number of cases can be 
anticipated (Strong, Kesavapany, & Pant, 2005; Chio et al., 2013). 
The neuropathological hallmark of ALS has been traditionally described as being two-
fold: the presence of degeneration of descending supraspinal motor tracts such as the 
corticospinal tract, and the loss of specific populations of cortical, brainstem and spinal 
motor neurons.  The latter has traditionally been associated with the presence of neuronal 
cytoplasmic inclusions (NCIs) that are composed of neuronal intermediate filaments, 
most typically neurofilaments. The contemporary view however also includes both NCIs 
and neuronal nuclear inclusions (NNIs) that are composed of a variety of proteins, the 
most common of which are either RNA binding proteins or proteins whose function 
impacts on RNA metabolism (Strong, 2010). Intraneuronal inclusions are pathological 
aggregations of misfolded protein that are not specific to ALS pathology, but have been 
observed in a diverse number of neurodegenerative disorders (for example, Alzheimer’s 
disease, Huntington’s disease, and Parkinson’s disease) (Roussel et al., 2013). Their 
presence can be seen as an indicator of pathology as inclusions are not often observed in 
individuals without disease phenotype.   
An important advance in our understanding of ALS has been the increasing awareness of 
a common link between these inclusions and the various forms of ALS that are familial in 
nature (fALS).  
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Table 1:  Functional groupings of genetic mutations associated with ALS 
Gene Locus Inheritance Alternative phenotype 
Enzymes 
   FIG4 6q21 Unknown PLS 
   SOD1 21q22.11 Dominant FTLD, PMA 
Expanded repeats 
   ATXN2 12q24.1 Dominant PMA 
   C9ORF72 9p21.2 Dominant FTLD 
RNA metabolism-related proteins 
   ANG 14q11.1-q11.2 Dominant FTLD 
   ARHGEF28 5q13.2 Unknown None 
   EWSR1 22q12.2 Unknown None 
   FUS 16q12 Both dominant 
and recessive 
FTLD 
   HNRNPA1 12q13.1 Dominant None 
   SETX 9q34.13 Dominant CMT or dHMN 
   TAF15 17q11.1-q11.2 Unknown None 
   TARDBP 1p36.22 Dominant FTLD 
Cytoskeleton proteins 
   NEFH 22q12.2 Uncertain None 
   PRPH 12q12-q13 Sporadic None 
   PFN1 17p13.3 Dominant None 
Intracellular transport proteins 
   CHMP2B 3p11.2 Dominant FTLD 
   DCTN1 2p13 Dominant None 
   VAPB 20q13.33 Dominant PMA, PLS 
   VCP 9p13.3 Dominant FTLD 
Ubiquitin-related proteins 
   SQSTM1 5q35 Dominant FTLD 
   UBQLN2 Xp11.21 Dominant FTLD 
Multifunctional proteins 
   OPTN 10p13 Dominant FTLD 
Others 
   ALS2 2q33.1 Recessive PLS 
   DAO 12q24 Dominant None 
   EPHA4 2q36.1 Unknown None 
   SPG11 15q21.1 Recessive None 
   Unknown 18q21 Dominant None 
   Unknown 15q15.1-21.1 Recessive None 
   Unknown 20p13 Dominant None 
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Gene abbreviations:  ANG: Angiogenin; ARHGEF28: Rho Guanine Nucleotide 
Exchange Factor; ATXN2: Ataxin 2; C9orf72: Chromosome 9 Open Reading Frame 72; 
CHMP2B: Charged Multivesicular Body Protein 2b; DAO: D-Amino-Acid Oxidase; 
DCTN1: Dynactin 1; EPHA4: Ephrin Type-A Receptor 4; EWSR1: Ewing Sarcoma 
Breakpoint Region 1; FIG4: Phosphatidylinositol 3,5-bisphosphate 5-phosphatase; FUS: 
Fused in Sarcoma/Translocated in Liposarcoma; HNRNPA1: Heterogeneous Nuclear 
Ribonucleoprotein A1; NEFH: High Molecular Weight Neurofilament; OPTN: 
Optineurin; p62/SQSTM1: Sequestosome-1; PFN1: Profilin 1; PRPH: Peripherin; SETX: 
Senataxin; SOD1: Superoxide Dismutase 1; SPG11: Spatacsin; TAF15: TATA-Binding 
Protein Associated Factor 2N; TARDBP: TAR DNA-Binding Protein of 43 kDa; 
UBQLN2: Ubiquilin 2; VAPB: Vesicle-Associated Membrane Protein-Associated 
Protein B and C; VCP: Valosin-Containing Protein. 
Phenotype abbreviations:  CMT: Charcot-Marie-Tooth Disease; dHMN: Distal 
Hereditary Motor Neuropathy; FTLD: Frontotemporal Lobar Degeneration; PLS: 
Primary Lateral Sclerosis; PMA: Progressive Muscular Atrophy. 
*Table adapted from: (Droppelmann, Campos-Melo, Ishtiaq, Volkening, & Strong, 2014)  
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As will be described, and as seen in Table 1, examples of such proteins for which genetic 
linkages have been found with fALS and for which neuronal inclusions have been 
observed include: mutant copper/zinc superoxide dismutase (mtSOD1) (Rosen et al., 
1993), TAR DNA-binding protein of 43 kDa (TDP-43) (Neumann et al., 2006), fused in 
sarcoma/translocated in liposarcoma (FUS) (Kwiatkowski, Jr. et al., 2009), and TATA-
binding protein-associated factor 2N (Couthouis et al., 2011). The aggregation and 
mutation of RNA-binding proteins and their genes in ALS is an emerging field which 
points towards disrupted RNA homeostasis as a pathogenic mechanism for motor neuron 
death in ALS. Following this RNA hypothesis of ALS pathogenesis, my thesis involves 
the study of a novel dual-function protein that our laboratory has discovered: Rho 
guanine nucleotide exchange factor (RGNEF; the human homologue of p190RhoGEF). 
RGNEF is both a signal transduction protein that can activate the RhoA signaling 
pathway and an RNA-binding protein that can affect the stability of target mRNA 
(Volkening, Leystra-Lantz, & Strong, 2010; Droppelmann, Keller, Campos-Melo, 
Volkening, & Strong, 2013). While similar to the previously mentioned RNA-binding 
proteins in that it forms pathological NCIs in ALS spinal motor neurons, RGNEF NCIs 
also colocalize with other RNA-binding protein inclusions such as TDP-43 and FUS 
(Keller et al., 2012).  
As previous studies have shown that ALS-related RNA-binding proteins, such as TDP-43 
and FUS, protect cells against cellular stress (Higashi et al., 2013; Sama et al., 2013), this 
thesis will examine the hypothesis that RGNEF participates in the cellular stress 
response. As I will describe, this hypothetical role in the stress response could be readily 
attributed to: (a) the participation of RGNEF in the formation of RNA stress granules as a 
component of the physiological response of the neuron to injury, or (b) the the singal 
transduction pathways mediated through RhoA activation as a result of RGNEF’s 
guanine exchange factor activity. In this chapter, I will describe the disease process of 
ALS, the proteins involved in ALS pathology, and how RGNEF may be contributing to 
ALS, including previous studies performed on the protein. 
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1.1 Background of amyotrophic lateral sclerosis  
The classical description of amyotrophic lateral sclerosis (ALS) is as a neurodegenerative 
disorder characterized by the progressive loss of both upper and lower motor neurons 
(Rowland & Shneider, 2001; Strong, 2010). Upper motor neurons synapse with other 
motor neurons while lower motor neurons synapse directly with muscle cells. Upper 
motor neurons, also termed descending supraspinal neurons, originate either from within 
the cortex (predominantly in the precentral motor cortex, but also in the supplementary 
motor cortex and the postcentral parietal cortex) or from within more primitive motor 
nuclei of the brainstem. The vast majority of these neurons cross at the level of the 
medulla to course through the ventral and lateral corticospinal tracts to innervate the 
contralateral spinal motor neurons. A separate population of upper motor neurons 
innervates select motor nuclei of the brainstem to control the oropharyngeal muscles 
through the bulbar motor neurons. Because both the upper and lower motor neurons are 
involved to varying degrees in ALS, the symptoms of ALS can differ from one individual 
to the next depending on which motor neurons are affected and to what degree (Purves et 
al., 2001). In general, the symptoms of ALS present first as wasting or weakness of the 
hands or legs (in which case it is termed limb onset), or as slurred speech and dysphagia 
(in which case it is termed bulbar onset). This difference is driven by the primary site of 
neuronal loss: spinal motor neurons or bulbar motor neurons, respectively (Rowland & 
Shneider, 2001).  
Death from ALS usually occurs within 3 to 5 years of symptom onset and generally from 
respiratory failure (Al-Chalabi & Hardiman, 2013). The disease course is however 
extremely heterogeneous and can be affected by the initial site of symptom onset, the 
time to diagnosis, or the age at symptom onset. For example, patients with limb onset 
ALS have a higher median survival than patients with bulbar onset ALS. Also, older 
patients have a lower median survival than younger patients (Scotton et al., 2012; Cui et 
al., 2014). 
Though ALS has been recognized as a discrete clinical and neuropathological entity since 
the time of its description by Jean-Martin Charcot in 1869, there is no cure and the 
underlying pathogenesis is only now becoming clearer (Charcot & Joffroy, 1869). It has 
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been suggested that the failure of many pharmacotherapeutic agents to meaningfully alter 
the course of ALS can in part be attributed to a significant delay in diagnosis from the 
time of symptom onset with affected patients thus being significantly advanced by the 
time of treatment intervention. However there remains no definitive diagnostic test or 
biomarker for ALS (Kiernan et al., 2011). Clinical neurologists utilize the El Escorial 
diagnostic criteria, created in 1994 and updated in 2007 to include the Awaji-Shima 
criteria, to diagnose ALS based on clinical, electrophysiological and genetic criteria 
(Brooks, 1994; Nodera, Izumi, & Kaji, 2007). When applied, these criteria are both 
sensitive and specific and have allowed for earlier diagnoses to be made for ALS patients 
(Chaudhuri et al., 1995; Costa, Swash, & de Carvalho, 2012).  Whilst there have thus 
been advances in the early diagnosis of ALS, there remains only a single approved 
pharmacotherapy for the disease process of ALS (although there are many successful 
symptomatic therapies). As such, an anti-glutamate compound called Riluzole remains 
the only approved treatment, and even this only extends survival of patients by 2 to 3 
months (Miller, Mitchell, & Moore, 2012). Currently, research is being performed to 
better characterize the molecular mechanisms of the disease in hopes of finding a 
targetable cause of the disease so that it can be arrested. 
1.2 Neuropathology and the disease process of ALS 
The neuropathological characterization of ALS can be considered in terms of both the 
conventional pathology and the more rapidly evolving contemporary pathology.   
Typically, there is a significant loss of muscle, thinning of the ventral spinal roots and 
atrophy of the spinal cord that is grossly observable (Strong et al., 2005). The loss of the 
descending supraspinal motor neurons gives rise to prominent pallor and gliosis of the 
ventral and lateral corticospinal tracts, while the loss of the cortical motor neurons gives 
rise to marked precentral cortical atrophy (Rowland & Shneider, 2001). In individuals 
where there is an associated frontotemporal dementia, there is significant frontal lobar 
atrophy often extending into the temporal and parietal lobes (Strong, 2001). 
At the light microscopic level, affected motor neurons exhibit a range of pathologies, 
including NCIs, NNIs and axonal swelling (neuroaxonal spheroids). Gliosis, evidenced 
by microglia and astrocyte proliferation also occurs and may negatively affect the 
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neuronal milieu in an inflammatory or excitotoxic manner, respectively (Strong et al., 
2005). 
 Neuronal cytoplasmic & nuclear inclusions in ALS 1.2.1
Neuronal inclusions are one of the hallmarks observed in degenerating motor neurons of 
ALS. There have been several different types of inclusions noted in ALS: Bunina bodies, 
hyaline conglomerate inclusions, and ubiquitinated inclusions (Xiao, McLean, & 
Robertson, 2006). Bunina bodies are granular, eosinophilic inclusions found in both 
dendrites and soma of ALS motor neurons that immunostain positive for proteinase 
inhibitor cystatin C, suggesting that they are of lysosomal origin (Okamoto, Hirai, Amari, 
Watanabe, & Sakurai, 1993). Hyaline conglomerate inclusions are argyrophilic, or silver-
stained, structures found in the perikarya, or soma, of ALS motor neurons. They are 
immunoreactive for neurofilaments and peripherin, implying that the disorganization of 
neuronal cytoskeleton is important in the pathology of ALS (Strong et al., 2005). 
Ubiquitinated inclusions can be dense and circular or fibrillar skeins and they are 
observed in the perikarya of ALS motor neurons (Leigh et al., 1991). These structures 
colocalize with other protein inclusions, as shown by immunoreactivity to such proteins 
as TAR DNA-binding protein of 43 kDa (TDP-43) (Neumann et al., 2006), RGNEF 
(Keller et al., 2012), fused in sarcoma (FUS) (Deng et al., 2010), RNA-binding motif 45 
protein (RBM-45) (Collins et al., 2012), and optineurin (OPTN) (Maruyama et al., 2010).  
Ubiquitinated inclusions are the most prevalent form of inclusion observed in ALS motor 
neurons (Piao et al., 2003). The function of ubiquitin is to bind and mark short-lived 
proteins for elimination primarily through the proteasome-degradation pathway. The 
accumulation of ubiquitinated proteins within ALS motor neurons suggests that the 
proteasome pathway is adversely affected and that a buildup of proteins marked for 
degradation eventually may lead to cellular damage and death (Bruijn, Miller, & 
Cleveland, 2004). In support of this, UBQLN2, a gene coding for the ubiquitin-like 
protein ubiquilin 2, is observed to be mutated in cases of familial ALS (Deng et al., 
2011). The ALS-associated mutation has been shown to impair the proteasome pathway.  
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The presence of ubiquitinated inclusions in ALS has also provided a valuable insight into 
mechanisms that may be disrupted through understanding the nature of the proteins that 
are integrated into the ubiquitinated inclusions. To date, the vast majority of these 
proteins have been associated with RNA metabolism, including TDP-43, RGNEF, FUS, 
RBM-45, and OPTN (Droppelmann et al., 2014).  
Related to the hypothesis of aberrant RNA metabolism is the altered mRNA levels of 
intermediate filament proteins in ALS and the observation that intermediate filament 
proteins are disorganized in ALS. Specifically, ALS motor neurons often show 
ubiquitinated inclusions of neurofilament and peripherin proteins (Wong, He, & Strong, 
2000). Moreover, mutations in the genes encoding high-molecular weight neurofilament 
(NEFH) and peripherin (PRPH) have been linked to cases of ALS (Figlewicz et al., 1994; 
Gros-Louis et al., 2004). It is hypothesized that when these intermediate filament proteins 
are mislocalized to intraneuronal inclusions in ALS, their function in maintaining the 
neuron’s structural integrity is compromised and processes such as axonal transport can 
be greatly affected.  Indeed, a mouse model of ALS where high molecular weight 
neurofilament (NFH) protein was overexpressed showed defects in axonal transport 
(Collard, Cote, & Julien, 1995). In addition, deficits in axonal transport are described as 
an early sign of disease in transgenic mouse models of ALS involving mutations in the 
gene encoding superoxide dismutase 1 (SOD1; model is often referenced as mtSOD1 
mouse model) (Williamson & Cleveland, 1999). However, it should be noted that 
neurofilament inclusions themselves may not necessarily be pathogenic. It was observed 
that by increasing the expression of either NFH or low molecular weight neurofilament 
(NFL) in a mtSOD1 transgenic mouse model of ALS, mice survived longer (Nguyen, 
Lariviere, & Julien, 2001). Although we are still unsure whether inclusions observed in 
ALS are a pathological cause or consequence of the disease, it is clear that their presence 
plays a significant role in the ongoing degeneration of motor neurons (Strong et al., 2005; 
Sanelli, Sopper, & Strong, 2004; Sanelli & Strong, 2007). 
 Microglial pathology and the role of oxidative injury in ALS 1.2.2
Microglia are a type of macrophage-like glial cell found throughout the nervous system. 
They are highly mobile cells that function to detect and remove pathogens and large 
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cellular debris from the nervous system (Raivich, 2005). However, microglia may also 
initiate neuroinflammation and cause profound neuronal damage. These two functions 
must be delicately balanced to preserve a healthy neuronal environment (Moisse & 
Strong, 2006). Microglia exist in two forms: a passive state where they monitor the 
neuronal environment for cellular insults through the extension of long cellular processes 
and an active state where they enlarge and gain their macrophage-like phagocytic 
function to capture the source of the cellular insult as well as release pro-inflammatory 
factors to recruit other immune cells to the area (Kreutzberg, 1996; Kalla et al., 2001).  
In ALS, microglia have proliferated and appear to be more active than in controls 
(Troost, van den Oord, & Vianney de Jong, 1990). In addition, mouse models of ALS 
have shown that diseased motor neurons are more susceptible to death upon microglia 
activation (Raoul et al., 2002). A similar observation has been made in vitro using 
immortalized motor neuron (NSC-34) and microglial (BV-2) cells (He, Wen, & Strong, 
2002). This increase microglial activity in ALS may contribute to an adverse 
inflammatory response causing increased neuronal apoptosis and oxidative damage in the 
area. Apoptosis may be caused by factors secreted from microglial cells, including tumor 
necrosis factor alpha, Fas ligand or nitric oxide (Moisse & Strong, 2006). Microglia can 
induce oxidative damage through a number of pathways, including the release of reactive 
oxygen species (ROS) such as superoxide and hydrogen peroxide, and the generation of 
reactive nitrating species (Banati, Gehrmann, Schubert, & Kreutzberg, 1993).  
Key to our underlying hypothesis, ALS motor neurons show signs of increased oxidative 
stress such as lipid peroxidation and protein glycoxidation (Shibata et al., 2001; Ferrante 
et al., 1997). Oxidative damage may also be caused through mitochondrial dysfunction or 
excitotoxicity. Mitochondrial dysfunction has been inferred to have a pathological role in 
ALS because of the observation of abnormal mitochondrial morphology and because of 
the effects of mtSOD1 protein in disrupting mitochondrial function (Strong et al., 2005). 
The pathogenic role of mtSOD1 in inducing motor neuron degeneration has been 
confirmed through studies of transgenic mice harbouring a variety of different SOD1 
mutations (Bruijn et al., 2004). Specifically for mitochondria, mtSOD1 has been shown 
to bind to a protein of the Bcl-2 family which interacts with the mitochondrial membrane 
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(Pasinelli et al., 2004). This interaction appears to cause cell death, likely through 
destabilization of the mitochondrial membrane leading to the release of pro-apoptotic 
factors and ROS (Brunelle & Letai, 2009).  
 The role of astrocytes and excitotoxicity in ALS 1.2.3
Astrocytes, similar to microglia, are another type of glial cell that have been implicated in 
ALS pathology. Astrocytes are not only critical to the formation of the blood brain 
barrier, but they play a role in regulating the extracellular milieu of neurons, including 
ion and neurotransmitter homeostasis (Tacconi, 1998). In ALS, astrocytes not only 
proliferate and appear to replace degenerating motor neurons with a glial scar, they may 
also contribute directly to motor neuron death – a hypothesis substantiated by 
observations from mtSOD1 mouse models (Levine, Kong, Nadler, & Xu, 1999). 
Moreover, the physiological role of astrocytes in regulating glutamate homeostasis, and 
thus intraneuronal calcium levels, is altered in ALS in a manner that has been suggested 
to either enhance or directly lead to motor neuron death through excitotoxic mechanisms 
(van Damme et al., 2007; Bruijn et al., 1997).  
The process of glutamate excitotoxicity involves the excitatory neurotransmitter 
glutamate and its cognate receptors. Excessive calcium influx has been shown to be 
associated with the induction of oxidative injury through the formation of reactive 
oxygen species (Heath & Shaw, 2002). Excitotoxicity may be caused by either the 
abundance of glutamate release from presynaptic neurons or the inability of glutamate 
transporters (called excitatory amnio acid transporters or EAAT) to clear glutamate from 
the synapse; both cases lead to the build-up of glutamate in the synapse. Astrocytes in 
ALS have been observed to have a significant depletion of the EAAT2 (or GLT-1) 
protein and a decrease in glutamate transport efficiency (Rothstein, Martin, & Kuncl, 
1992; Rothstein, van Kammen, Levey, Martin, & Kuncl, 1995).  
There is increasing evidence to suggest that motor neuron degeneration in ALS is 
associated with alterations in autophagy in addition to significant alterations in the 
proteasome-degradative pathway (Kabashi & Durham, 2006). Autophagy is similar to the 
proteasome-degradative pathway in that they both act as a mechanism of quality control 
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in the cell. The process of autophagy involves the breakdown of proteins and organelles 
that are no longer necessary within cytoplasmic vesicles called autophagosomes. Support 
for the hypothesis that autophagy is disturbed in ALS has been provided by the finding in 
ALS of mutations in the gene SQSTM1 which encodes p62, or sequestosome 1. p62 is an 
adapter protein that can facilitate the localization of ubiquitinated proteins and organelles 
to autophagosomes through an interaction with microtubule-associated protein 1 light 
chain 3 (LC3) protein that is bound to autophagosome membranes (Kim, Hailey, Mullen, 
& Lippincott-Schwartz, 2008; Pankiv et al., 2007). Protein aggregates and dysfunctional 
mitochondria observed within ALS motor neurons often colocalize with p62 and may be 
indicative of the disruption of autophagy resulting in non-clearance of these pathological 
structures (Chen, Zhang, Song, & Le, 2012). 
1.3 The three known variants of ALS  
Three variants of ALS are recognized:  the classical sporadic variant (sALS), the familial 
variant (fALS) and the Western Pacific variant. The latter variant occurs in a 
hyperendemic focus amongst the Chamorro peoples of Guam and the Japanese 
inhabitants of the Kii Peninsula (Garruto, 2006). Since its description in 1945, the 
incidence of Guamanian ALS has decreased dramatically (Garruto, Yanagihara, & 
Gajdusek, 1985). This has led to the proposal that ALS in the Western Pacific is an 
example of an environmental trigger for the disease, perhaps in association with 
enhanced genetic susceptibility, for which two hypotheses have been advanced. The first 
involves Cycas circinalis toxicity and in particular the biomagnification of the neurotoxin 
beta-methylamino L-alanine (BMAA) through either the consumption of flying foxes that 
eat the seeds or through the use of cycad flour in traditional foodstuffs (Cox & Sacks, 
2002). However, this seemed unlikely since animals would exhibit no findings of ALS 
after accumulating large amounts of BMAA and the fact that free BMAA could not be 
detected in Chamorros with or without disease symptoms (Steele & McGeer, 2008). A 
second hypothesis cites the modernization and westernization of Guamanian society for 
the decline in Guamanian ALS as traditional foods and lifestyle have been changed as a 
result of the western influence from the United States. Currently, the etiology of 
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Guamanian ALS remains unresolved and research continues as cases are still observed, 
albeit at a lower incidence (Plato et al., 2003). 
Although the remaining cases of ALS (accounting for over 95% of those observed 
worldwide) can be considered either sALS or fALS, this dichotomizaton is increasingly 
being challenged as our understanding of the pathogenesis of ALS increases 
exponentially. Much of our current understanding of ALS can be attributed to the genetic 
discoveries made in fALS. In fact, there may be a genetic component to all forms of ALS 
(Al-Chalabi et al., 2012), a hypothesis strengthened by the observation of increased ALS 
risk to relatives of patients with apparent sALS (Hanby et al., 2011). 
The importance of this increasing overlap between sALS and fALS lies in the 
commonality of the NCIs and NNIs between all of the variants.  Indeed, in a blinded 
study of both fALS and sALS, our laboratory was unable to differentiate amongst these 
two variants of ALS using immunohistochemical markers of both the traditional 
(intermediate filament inclusions) and contemporary (RNA binding proteins) pathologies 
of ALS (Keller et al., 2012). Given this, it is germane to our hypothesis to briefly 
examine the various genetic mutations associated with ALS (Table 1). The common 
thread underlying the mechanism of action of many of the pathogenic mutations 
associated with ALS is firstly a fundamental alteration in RNA metabolism, and secondly 
for many of the gene products, an alteration specifically in the low molecular weight 
neurofilament RNA mRNA (NEFL mRNA) stability. As will be also discussed, RGNEF 
lies at the intersection of both NEFL mRNA stability regulation and the cellular response 
to oxidative stress.   
1.4 Gene mutations associated with ALS 
 Intermediate filaments 1.4.1
The neuronal intermediate filaments are a family of cytoskeletal proteins that include 
neurofilaments, peripherin, vimentin, nestin, and α-internexin (Szaro & Strong, 2010).  
As shown in figure 1, they share common features of an N-terminus head domain which 
regulates filament assembly, a central coiled-coil (α-helical coil) domain that facilitates 
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protein-protein interactions, and a C-terminus tail domain that contains phosphorylation 
sites of varying length which are key to modulating neuronal structure.   
Neurofilaments (NFs) are found abundantly within neurons and serve to provide 
structural stability within the cell, determine the axonal thickness (or calibre) and 
improve axonal outgrowth (Szaro & Strong, 2010). There are three different isoforms of 
neurofilament: low molecular weight neurofilament (NFL; 66 kDa), medium molecular 
weight neurofilament (NFM; approx. 160 kDa), and high molecular weight neurofilament 
(NFH; approx. 220 kDa). The intact NF protein is a heteropolymer of the individual NF 
subunit proteins in which NFL must first dimerize either as a homopolymer or as a 
heteropolymer with either α-internexin, peripherin or vimentin. NFM and NFH then 
polymerize with this core unit though interactions in their N-terminus domains, while 
their highly phosphorylated C-terminus domains project from this core assembly. Any 
disruption of this assembly, as for instance will occur with a loss of NFL protein thus 
altering the NF protein stoichiometry, will lead to NF inclusions and motor neuron loss 
(Lee & Cleveland, 1996; Lee, Xu, Wong, & Cleveland, 1993; Gama Sosa et al., 2003; 
Cote, Collard, & Julien, 1993).  
As described earlier, the accumulation of neurofilament within NCIs is a common 
pathological hallmark in ALS (Al-Chalabi et al., 2012; Hirano, Donnenfeld, Sasaki, & 
Nakano, 1984; Sasaki & Maruyama, 1992). Key to our understanding of the pathogenesis 
of ALS and to the role of RGNEF in the disease process, there is convincing evidence 
across multiple labs, including ours, that the levels of NEFL mRNA are selectively 
suppressed within ALS spinal motor neurons, within transgenic mouse models of ALS, 
and within induced pluripotent stem cell models of ALS (Bergeron et al., 1994; Wong et 
al., 2000; Menzies et al., 2002; Chen et al., 2014). This has been postulated to contribute 
directly to pathological NCI formation.  
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Figure 1:  Comparing different intermediate filament proteins found in neurons. All 
the neuronal intermediate filament proteins share a similar structure consisting of an N-
terminal head domain, a central α-helical core, and a C-terminal tail domain. The α-
helical cores are required for polymerization, while the C-terminal tails and N-terminal 
heads regulate filament assembly and neuronal structure respectively. Longer tail 
domains indicate a greater opportunity for post-translational protein modifications such 
as phosphorylation which affect the spatial interactions between the intermediate filament 
proteins and consequently the neuronal structure as well. Interestingly, peripherin and α-
internexin share a similarity in size as NFL. This similarity may explain the replacement 
of peripherin and α-internexin by NFL in mature neurons. 
IF = intermediate filament; NFL = low weight neurofilament; NFM = medium weight 
neurofilament; NFH = high weight neurofilament. 
*Figure adapted from: (Szaro & Strong, 2010) 
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In addition to this selective suppression of NEFL mRNA in ALS, mutations in NEFH 
have been observed in ALS (Al-Chalabi et al., 2012). Although this occurs in less than 
1% of the sALS population, this is further evidence of the role of alterations in NF 
metabolism as key to the pathogenesis of ALS even if only as potential risk factors 
(Gros-Louis, Gaspar, & Rouleau, 2006).  
Peripherin is an intermediate filament protein found within peripheral neurons of the 
nervous system. While sharing a number of characteristics of NFs, peripherin appears 
earlier than neurofilament proteins during development and is required for axonal 
elongation, an observation recapitulated in regenerating axons after neuronal injury. With 
maturation, peripherin is largely replaced by NFs (Szaro & Strong, 2010). Similar to 
NEFH, the gene encoding peripherin, PRPH, has rarely been found to be mutated in 
sALS, suggesting a potential role in disease susceptibility (Gros-Louis et al., 2004). This 
postulate is supported by the observation that mice overexpressing peripherin exhibit 
progressive, age-dependent motor neuron degeneration (Millecamps, Robertson, 
Lariviere, Mallet, & Julien, 2006). Moreover, peripherin has been found within 
ubiquitinated inclusions of ALS motor neurons and transgenic mtSOD1 mouse models of 
ALS show peripherin inclusions as an early sign of disease (Corbo & Hays, 1992). 
Interestingly, the levels of peripherin protein are altered in ALS and this alteration may 
be a result of the increased levels of PRPH mRNA seen in ALS cases. Consequently, the 
disturbance in peripherin levels may be a result of aberrant RNA homeostasis, similarly 
described for NFs, and lending support to the hypothesis that RNA metabolism is altered 
in ALS. 
Although α-internexin is very similar in molecular weight and structure to NFL (Lee & 
Cleveland, 1996), it differs in being expressed earlier in neuronal development and in 
being restricted in expression to the central nervous system (Szaro & Strong, 2010). As 
neurons mature, NFL protein gradually replaces α-internexin, though α-internexin is not 
completely replaced and has been shown to be able to co-assemble with NFs (Yuan et al., 
2006). Thus, similar to peripherin, problems in α-internexin assembly could lead to 
problems in NF assembly. In contrast to both NFs and peripherin, there have been to date 
no reports of mutations in the gene encoding α-internexin or of α-internexin 
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immunoreactive NCIs in ALS. However, α-internexin has been seen to aggregate and 
form neuronal spheroids in transgenic mtSOD1 mouse models suggesting that it can 
indeed play a role in the induction of motor neuron degeneration (Wong et al., 2000; 
King, Blizzard, Southam, Vickers, & Dickson, 2012).  
 Copper/zinc superoxide dismutase 1.4.2
Superoxide Dismutase 1 (SOD1), the gene that encodes for the copper/zinc superoxide 
dismutase (SOD1), was the first gene to be linked to fALS and accounts for about 12% of 
all fALS cases (Rosen et al., 1993; Chio et al., 2008). Although transgenic mouse models 
of mtSOD1 have proven to be useful in understanding the pathogenic mechanisms of 
mtSOD1 toxicity (Pasinelli et al., 2004), there remains controversy regarding the extent 
to which this model of ALS truly recapitulates the disease process of ALS (Ludolph et 
al., 2007). This is especially due to its failure to predict responsiveness to experimental 
therapies for the treatment fALS. 
SOD1 is responsible for removing reactive oxygen species in the cell, specifically 
converting the highly-reactive superoxide radical into hydrogen peroxide (Gurney et al., 
1994). Though most mutations in the SOD1 gene inhibit the SOD1 protein’s dismutase 
ability, some mutations do not affect it at all, though still maintaining a disease 
phenotype. This suggests that the protein may be gaining toxic function (Al-Chalabi et 
al., 2012). Although a number of potential mechanisms of mtSOD1-mediated 
neurotoxicity have been postulated, our lab has demonstrated that one such gain of 
function is the ability for mtSOD1 to interact directly with the NEFL mRNA 3’ 
untranslated region (3’ UTR) and destabilize it, leading to a marked alteration in NF 
protein stoichiometry (Ge, Wen, Strong, Leystra-Lantz, & Strong, 2005).  In patients 
harbouring mtSOD1, NCIs immunoreactive with antibodies to SOD1 are rarely observed 
and have been postulated to impair axonal transport (Bruijn et al., 1998). 
 Chromosome 9 open reading frame 72 1.4.3
C9ORF72 is a newly discovered gene involved in both sALS and fALS, now accounting 
for the majority of genetically originating cases. The mutation of the gene is observed as 
a massive intronic hexanucleotide (GGGCC) repeat expansion (DeJesus-Hernandez et al., 
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2011; Renton et al., 2011). The number of repeat expansions found within ALS patients 
ranges between 600 to 2,000 repeats, while normal individuals appear to have about 23 
repeats (Al-Chalabi et al., 2012; DeJesus-Hernandez et al., 2011). However, the exact 
threshold of repeats necessary for disease induction by C9ORF72 is unknown due to 
difficulties in sequencing GC rich DNA (Stepto, Gallo, Shaw, & Hirth, 2014). Currently, 
C9ORF72 mutations account for about 40% of all fALS cases (Renton, Chio, & Traynor, 
2014). 
The protein product of C9ORF72 is not known, though bioinformatics studies suggest 
that the protein is related to Differentially Expressed in Normal and Neoplasia (DNEN) - 
a GDP/GTP exchange factor that can activate Rab GTPases (Levine, Daniels, Gatta, 
Wong, & Hayes, 2013). Rab GTPases may be important in neurodegeneration because of 
their effects on membrane vesicle trafficking (Stenmark, 2009). 
There are currently three somewhat overlapping hypothesis regarding the mechanism of 
toxicity of C9ORF72, including a loss of function resulting from failure of mRNA 
translation, toxic gain of function from the formation of RNA foci and RNA-binding 
protein sequestration, and repeat-associated non-ATG (RAN) translation generating 
dipeptide repeat proteins (Stepto et al., 2014). Although much work remains to be done, 
RNA-binding protein sequestration by RNA foci and RAN translation protein products 
appear to be of significance in the toxic mechanism of C9ORF72 (Zu et al., 2013; Lee et 
al., 2013). Conversely, loss of function of C9ORF72 protein seems to be less important in 
disease pathogenesis (Fratta et al., 2013). 
 Ataxin-2 1.4.4
Ataxin-2 is a protein that has been functionally linked to many aspects of mRNA 
processing, including polyadenylation and micro RNA (miRNA) synthesis (Blokhuis, 
Groen, Koppers, van den Berg, & Pasterkamp, 2013). Similar to the pathogenic 
expansion of GGGCC repeats in C9ORF72, the gene for ataxin-2, ATXN2 contains 
pathogenic CAG nucleotide expansions, although to a less impressive extent (Elden et al., 
2010; Liu et al., 2013). Although the exact mechanism by which the pathogenic 
expansion of CAG repeats in ataxin-2 induce neuronal pathology is unknown, it is known 
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that the number of repeats is a critical determinant of disease induction:  CAG repeat 
length between 27 and 33 are linked to ALS (Elden et al., 2010) while longer repeats are 
associated with the disease spinocerebellar ataxia 2 (SCA2) (Hart & Gitler, 2012). SCA2 
differs from ALS as it is a disorder of cerebellar function which is only rarely associated 
with motor neuron disease degeneration.  The importance of ataxin-2 in mRNA 
processing implies that its dysfunction can lead to impairments in mRNA metabolism, 
further supporting the RNA hypothesis of ALS. 
 TAR DNA-binding protein of 43 kDa 1.4.5
TAR DNA-binding protein of 43 kDa was originally discovered in human 
immunodeficiency virus (HIV) as a DNA-binding protein that could repress in vitro 
transcription of HIV-1, a gene expressed by the human immunodeficiency virus (HIV) 
(Ou, Wu, Harrich, Garcia-Martinez, & Gaynor, 1995). TDP-43 was also found to have a 
role in splicing the cystic fibrosis transmembrane conductance regulator (CFTR) (Buratti 
et al., 2001). In 2006, two groups discovered that TDP-43 was also the major component 
of ubiquitinated aggregates observed in ALS motor neurons, thus implicating this protein 
in the disease pathology (Neumann et al., 2006; Arai et al., 2006).  Shortly thereafter, our 
laboratory demonstrated that TDP-43 was a stability determinant for NEFL mRNA 
through a direct interaction with its 3’ UTR (Strong et al., 2007).   
TDP-43 is found ubiquitously in cells and normally appears in the nucleus where it 
participates at multiple levels in both DNA and RNA processing, including splicing, 
miRNA biogenesis, RNA transport, and stress granule formation (Ling, Polymenidou, & 
Cleveland, 2013). In response to cellular injury or stress, neuronal TDP-43 expression is 
massively up-regulated and the protein is translocated from the nucleus to the cytoplasm 
where it is postulated to be integral to the stabilization of mRNAs through its 
incorporation into both transport and stress granules, discussed further below (Moisse et 
al., 2009). 
Interestingly, TDP-43 expression is predominantly cytoplasmic in the motor neurons in 
ALS where it also forms NCIs. Concomitant with this aggregate formation, there is a loss 
of nuclear expression, in part due to a loss of cytosolic-nuclear transport (Lee, Lee, & 
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Trojanowski, 2012). While the exact mechanism by which TDP-43 forms pathological 
NCIs is not clear, it does appear to be dependent on its C-terminal glycine region which 
is normally responsible for its protein-protein interactions (Igaz et al., 2009).  
Mutations in the gene encoding TDP-43 (TARDBP) are observed in approximately 4% of 
all fALS cases, with all but one of the documented mutations being found within the C-
terminal glycine region of TDP-43 (Sreedharan et al., 2008).  
 Fused in sarcoma/translocated in liposarcoma 1.4.6
Similar to TDP-43, Fused in Sarcoma/Translocated in Liposarcoma (FUS or FUS/TLS) is 
an RNA-binding protein that has been observed to form pathological NCIs in ALS motor 
neurons and is mutated in approximately 4% of all fALS cases (Renton et al., 2014).  
Under physiological conditions, FUS is normally localized to the nucleus and has many 
similar functions to TDP-43 such as participation in RNA splicing and transcription, in 
addition to miRNA processing (Ling et al., 2013). Also like TDP-43, FUS can associate 
with RNA granules (Lagier-Tourenne et al., 2012). In ALS motor neurons, FUS becomes 
mostly cytoplasmic and forms protein aggregates. FUS has also been shown to be able to 
bind murine NEFL mRNA, further solidifying the linkage between known genetic 
linkages in ALS and the metabolism of NEFL mRNA (Kwiatkowski, Jr. et al., 2009). 
 Ewing’s sarcoma protein and TATA-binding protein associated factor 2N 1.4.7
FUS protein belongs to a family of proteins called the FET proteins (FUS, EWS, TAF15) 
that also contains two other members: Ewing’s sarcoma protein (EWS) encoded by the 
gene EWSR1 and TATA-binding protein associated factor 2N (TAF15) encoded by the 
gene TAF15. Both EWSR1 and TAF15 have been shown to be mutated in cases of ALS. 
All three FET proteins are very similar in structure (Tan & Manley, 2009) and both EWS 
and TAF15 are also observed to be mislocated to the cytoplasm as punctate granules in 
ALS motor neurons (Couthouis et al., 2012; Couthouis et al., 2011). However, in spite of 
their close functional relationship, FUS NCIs in ALS do not colocalize with EWS or 
TAF15 NCIs (Neumann et al., 2011). Similar to TDP-43 and FUS, EWS and TAF15 
normally function in regulating RNA processes such as transcriptional activation, 
splicing, miRNA processing, and RNA granule formation (Tan & Manley, 2009).  
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 Angiogenin 1.4.8
Angiogenin is a protein that is induced by hypoxia to elicit angiogenesis and cell 
division. Specifically, it is a ribonucleolytic protein that functions in the nucleus to 
stimulate ribosomal RNA (rRNA) transcription through its binding to a promoter in the 
ribosomal DNA (Li & Hu, 2012). This function is intricately related to the function of 
another angiogenic protein called vascular endothelial growth factor (VEGF) (Kishimoto, 
Liu, Tsuji, Olson, & Hu, 2005). Angiogenin is also found within motor neurons and 
indeed the gene that encodes it, ANG, has been described as a susceptibility gene for ALS 
(Greenway et al., 2006). In fact, the mutations described have been associated with a loss 
of its functioning (Wu et al., 2007). Within motor neurons, angiogenin has been 
described to have neuroprotective functions, and so the loss of its function in ALS-related 
ANG mutations may provide a causative link for angiogenin’s role in ALS (Subramanian, 
Crabtree, & Acharya, 2008; Kieran et al., 2008). In addition, its connection to the 
function of VEGF provides further evidence of angiogenin’s role in ALS pathology as 
transgenic mouse models with VEGF deletions exhibit motor neuron cell death 
(Oosthuyse et al., 2001). 
 Heterogeneous nuclear ribonucleoprotein A1 1.4.9
Heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) is an RNA-binding protein 
with a diverse roles in the nucleus. Similar to TDP-43 and the FET family of proteins, 
hnRNP A1 has been shown to process mRNAs through splicing, to shuttle mature mRNA 
through the nuclear pore complex, and to interact with the Drosha complex in miRNA 
biogenesis (Bekenstein & Soreq, 2013). HNRNPA1, the gene encoding hnRNP A1, is 
rarely mutated in ALS (Kim et al., 2013; Calini et al., 2013). Interaction between hnRNP 
A1 and TDP-43 has also been observed, implying that dysfunction in one protein could 
lead to dysfunction in the other. 
 Senataxin 1.4.10
Senataxin is a protein predicted to be an RNA helicase that has been implicated in the 
disease process of ALS. Mutations in its gene, SETX, are associated with an autosomal 
dominant form of juvenile ALS known as ALS4 (Chen et al., 2004). However, its role in 
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causing pathology remains unknown. Normally, RNA helicases appear to function to 
rearrange RNA-protein interactions though an unwinding of short, double stranded RNA 
sequences (Tanner & Linder, 2001). By extension, RNA helicases have been related to 
mRNA splicing and mRNA translational initiation and termination (Gustafson & Wessel, 
2010). Therefore, like TDP-43, the FET family proteins and hnRNP A1, senataxin may 
be contributing to ALS pathology via a disruption in RNA metabolism (Strong, 2010). 
1.5 RNA granules  
A commonality of the proteins described above is that they can all be linked to aberrant 
RNA metabolism in ALS, including C9ORF72 which does not directly bind RNA but 
appears to have a toxic RNA gain of function through its sequestration of RNA binding 
proteins or its induction of RNA translation (Strong, 2010; Strong et al., 2007; Ge et al., 
2005; Stepto et al., 2014; Kim et al., 2013; Chen et al., 2004; Couthouis et al., 2012; 
Couthouis et al., 2011). Because of the many RNA processing duties of RNA-binding 
proteins like TDP-43 and the FET family of proteins, there are many areas in which RNA 
metabolism may go wrong in ALS. Nuclear splicing, miRNA processing, and intron 
stabilization may all be affected by the disease process.  
Our laboratory has been particularly interested in the role of these various RNA 
interacting proteins in the formation and function of RNA granules (or ribonucleoprotein 
particles, RNPs). RNA granules are macromolecular structures within the cell composed 
of RNA, RNA binding proteins and all of the regulatory proteins for controlling localized 
RNA translation, silencing or destruction (Strong, 2010). They thus represent a critical 
structure in RNA metabolism, and although controversial, have been postulated to be the 
precursor to NCIs in which RNA binding proteins have been incorporated (Wolozin, 
2012; Ling et al., 2013). Within neurons, there are currently four known RNA granules: 
stress granules, transport granules, processing bodies, and nuclear paraspeckles (Table 2).  
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Table 2:  Types of RNA granules found in neurons 
Name Marker Function References 
Stress Granules TIA1 protein Forms in response 
to a stress (e.g. heat 
shock, oxidative 
stress, etc.) and 
appears to play an 
important role in 
deciding mRNA 
fate (storage or 
decay) during 
stress 
Kedersha et al., 
2000 
Transport Granules Staufen protein Ubiquitous within 
the neuron and 
appears to shuttle 
mRNAs 
throughout the cell 
for localized 
translation of 
protein 
Martin & Ephrussi, 
2009 
Processing Bodies XRN1 protein Ubiquitous within 
neurons, serving as 
a hub for storing 
and degrading 
mRNA and works 
closely with stress 
granules 
Ingelfinger et al., 
2002 
Nuclear Paraspeckles NEAT1 long non-
coding RNA 
Stores RNAs 
within nuclei and 
selectively releases 
them under stress 
conditions 
Shelkovnikova et 
al., 2014 
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 Stress granules 1.5.1
Stress granules (SG) are not present in the resting state, but are formed when cells are 
exposed to stressors such as heat shock, oxidative, or osmotic stressors (Kedersha, Gupta, 
Li, Miller, & Anderson, 1999; Sama et al., 2013). These granules contain mRNA in the 
presence of not only RNA-binding proteins that modulate the stability and translational 
activation of the mRNAs, but also a number of proteins that can be used in their 
characterization, for instance T-cell intracellular antigen 1 (TIA-1) and a Ras GAP SH3 
binding protein (G3BP) (Kedersha et al., 1999; Tourriere et al., 2003). TIA-1 and G3BP 
are known to regulate stress granule assembly, which is both rapid to combat stress 
efficiently and transient in order to disassemble when the stressor has been removed 
(Anderson & Kedersha, 2009; Wolozin, 2012). In addition, TIA-1 protein has shown to 
rapidly shuttle in and out of SGs (Kedersha et al., 2000). SGs are dynamic structures that 
may act as foci of triage for RNA, deciding the fate of individual transcripts: whether to 
be stored safely in SGs or degraded in processing bodies (a type of RNA granule 
described below) (Anderson & Kedersha, 2008). 
The formation of SGs also appears to be protective against a stress. When the formation 
of SG is inhibited, the survival of these cells significantly decreases compared to 
uninhibited cells in response to a stressor (Eisinger-Mathason et al., 2008). Also, 
apoptosis-promoting factors such as tumor necrosis factor α (TNFα) and receptor for 
activated C kinase (RACK1) have been observed to be sequestered in SGs, suggesting an 
anti-apoptotic  function (Kim, Back, Kim, Ryu, & Jang, 2005; Arimoto, Fukuda, Imajoh-
Ohmi, Saito, & Takekawa, 2008). Although some doubts remain regarding the 
conclusions of these studies, namely that blocking SG assembly with drugs such as 
cycloheximide may be affecting several other cellular processes, SGs seem to be 
intimately involved in cellular survival during a stress (Kedersha, Ivanov, & Anderson, 
2013). 
Recently, stress granule formation has become an interesting topic of discussion 
regarding the protein aggregates observed in ALS. This interest may be attributed to the 
role of ALS-related RNA-binding proteins in the formation of SGs. Indeed, TDP-43 and 
FUS have both been observed to colocalize with TIA-1 positive stress granules (Sama et 
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al., 2013; Liu-Yesucevitz et al., 2010). Taken together, a strong implication is made for 
the involvement of pathological stress granules in ALS. Indeed, stress granules can be 
observed in the ALS cortical tissues (Liu-Yesucevitz et al., 2010). The idea of 
irreversible SG formation leading to insoluble aggregates has been raised as a possible 
etiology for the aggregates seen ALS. This argument is strengthened by the fact that 
many SG associated RNA binding proteins, such as TIA-1, contain glycine-rich prion-
like domains (Gilks et al., 2004). It has been hypothesized that these domains have the 
potential to become pathological and form irreversible amyloid aggregates, similar to 
prion protein itself (Arimoto et al., 2008; Wolozin, 2012). However, this hypothesis has 
yet to be proven. 
 Transport granules 1.5.2
Transport granules are responsible for transporting mRNA to specific sites for localized 
protein translation (Martin & Ephrussi, 2009). Unlike SG’s, transport granules are 
necessary for normal cellular functioning and can be found throughout the cell under 
physiological conditions. Staufen is a key constituent of transport granules that can bind 
stem-loop structures within mRNA 3’ UTRs and transport them to sites, such as neuronal 
dendrites, for localized protein translation (Ferrandon, Koch, Westhof, & Nusslein-
Volhard, 1997; Kiebler et al., 1999). 
Defects in RNA transport have been implicated in various neurodegenerative diseases 
including fragile X mental retardation syndrome and spinocerebellar ataxia 2 (Tosar et 
al., 2012). Motor neuron degeneration has been indirectly linked to aberrant RNA 
transport through the finding of a mutation in the motor protein dynactin in ALS (Puls et 
al., 2003). TDP-43 has also shown to associate with staufen-positive transport granules, 
with ALS-related mutations impairing the function of these transport granules, further 
suggesting the involvement of transport granules in ALS pathology (Alami et al., 2014; 
Volkening, Leystra-Lantz, Yang, Jaffee, & Strong, 2009). 
 Processing bodies 1.5.3
Processing bodies (PB) function to store mRNAs in a translationally quiescent form so 
that they can later be degraded or returned for translation (Brengues, Teixeira, & Parker, 
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2005; Parker & Sheth, 2007). Similar to SGs, PBs are upregulated during a stressor, 
though PBs are also observed in the absence of stress and therefore form independently 
from SGs (Li, King, Shorter, & Gitler, 2013; Kedersha et al., 2005). Interestingly, SG and 
PB share certain RNA binding proteins and this sharing may be related to the ability of 
SG and PB to interact with each other (Kedersha et al., 2005). However, the two granules 
differ in that PBs contain RNA degradation machinery such as Decapping enzyme 1 
(DCP1A) and 5’-3’ exoribonuclease 1 (XRN1) while SGs contain translation initiation 
machinery such as Poly(A)-binding protein 1 (PABP1) (Kedersha et al., 1999; Eulalio, 
Behm-Ansmant, & Izaurralde, 2007; Ingelfinger, Arndt-Jovin, Luhrmann, & Achsel, 
2002). It is worth noting that the dynamic conditions of both PBs and SGs further SGs 
role as a site of RNA triage during stress, and that both granule types are necessary for 
this task (Anderson & Kedersha, 2008).   
The relationship between PBs and ALS pathology has not been studied in detail. It is 
worthwhile to note that, like SGs, PBs colocalize with TDP43 and FUS (Volkening et al., 
2009; Li et al., 2013). In addition, as PBs are similar to SGs they may also be implicated 
in the pathogenic conversion of granule to aggregate. This is because many of the RNA 
binding proteins associated with PBs, like SGs, contain prion-like domains which have 
the potential to form irreversible aggregates within the cytoplasm (Wolozin, 2012).  
 Nuclear paraspeckles 1.5.4
Nuclear paraspeckles are a type of RNA granule that, unlike the other three granules 
described, are restricted to the nucleus. Initially discovered in 2002 by Fox et al. (Fox et 
al., 2002), paraspeckles are formed from the long non-coding RNA (lncRNA) called 
nuclear-enriched abundant transcript 1 (NEAT1) and its constituent RNA-binding 
proteins (Nakagawa & Hirose, 2012). Protein components shuttle rapidly between other 
structures in the nucleus, whereas NEAT1 lncRNA is structurally vital to the formation of 
paraspeckles (Mao, Sunwoo, Zhang, & Spector, 2011). Paraspeckles appear to function 
by sequestering specific RNAs, preventing their release from the nucleus unless the cell 
encounters a stress such as transcriptional inhibition. Upon stress, the transcripts are 
released from the paraspeckles (Nakagawa & Hirose, 2012).  
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Paraspeckles have been recently implicated in the early stages of ALS pathology. ALS 
motor neurons show increased formation of paraspeckles compared to control motor 
neurons while both TDP-43 and FUS colocalize with paraspeckles (Nishimoto et al., 
2013). It is currently unknown whether paraspeckles are pathological or protective in 
ALS motor neurons, though Shelkovnikova et al. found that the loss of FUS from the 
nucleus destabilizes paraspeckles and may leave cells vulnerable to stress 
(Shelkovnikova, Robinson, Troakes, Ninkina, & Buchman, 2014). 
1.6 Rho guanine nucleotide exchange factor 
Our laboratory recently discovered that Rho guanine nucleotide exchange factor 
(RGNEF) forms pathological NCIs in ALS spinal motor neurons (Keller et al., 2012). As 
its name suggests, RGNEF can bind and activate small GTPase RhoA using two 
domains: a Dbl-homology domain and a Pleckstrin-homology domain (Fig. 2) 
(Volkening et al., 2010). The Dbl-homology domain is responsible for the GDP/GTP 
exchange while the Pleckstrin-homology domain allows the protein to locate to the cell 
membrane to bind RhoA (Zheng, 2001). RGNEF is also an RNA binding protein and has 
been shown to bind and destabilize NEFL mRNA (Droppelmann et al., 2013; Volkening 
et al., 2010). To date it is the only known RNA binding protein that also participates in 
RhoA activation. In addition, ARHGEF28, the gene that encodes RGNEF, has been 
shown to be mutated in both sALS and fALS, although this observation is exceptionally 
rare (Ma et al., 2014; Droppelmann et al., 2013). This mutation involves a deletion of a 
single nucleotide leading to a either a frameshift mutation or a splicing mutation within 
the gene. The result is a truncated RGNEF product predicted, respectively, to be either 
319 or 259 amino acids long, which is a massive difference compared to the normal 1731 
amino acid length of RGNEF (Droppelmann et al., 2013). Taken together, these 
characteristics of RGNEF strongly implicate the protein in ALS pathogenesis.  
p190RhoGEF is the murine homologue of RGNEF. It was originally discovered as a 
guanine exchange factor protein that specifically activated the small GTP-ase RhoA 
(Gebbink et al., 1997; van Horck, Ahmadian, Haeusler, Moolenaar, & Kranenburg, 
2001). Mutations in p190RhoGEF that alter its interaction with murine NEFL mRNA  
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Figure 2:  Comparing the protein structures of RGNEF and p190RhoGEF. RGNEF 
is longer than p190RhoGEF by 38 amino acids and this difference in length has also 
caused some differences in domain locations. Both proteins share similar domains based 
on previous studies and protein analysis by UniProt, however RGNEF destabilizes NEFL 
mRNA while p190RhoGEF stabilizes it. Both proteins utilize their DH/PH domains to 
activate the cell signaling small GTPase RhoA.  
L = leucine rich domain; Zn = Zinc-binding domain; DH = Dbl homology domain; PH = 
Pleckstrin homology domain; RBD = RNA-binding domain. 
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give rise to a motor neuron degeneration in which NF immunoreactive NCIs are 
prominent (Lin, Zhai, & Schlaepfer, 2005). Though p190RhoGEF has been shown by 
northern blotting to be found in several tissues, including kidney and lung, its presence in 
the brain was of particular interest due to its ability to bind and stabilize NEFL mRNA 
(Gebbink et al., 1997; Canete-Soler, Wu, Zhai, Shamim, & Schlaepfer, 2001). 
p190RhoGEF also forms aggregates that co-localize with NFL protein aggregates when 
NEFL mRNA and its 3’ UTR are overexpressed in Neuro 2A cells, a mouse neuronal cell 
line (Lin et al., 2005). 
It has been suggested that p190RhoGEF and NFL protein exist in a complex with each 
other where p190RhoGEF modulates levels of both NEFL mRNA and NFL oligomers to 
restrict the self-assembly of NFL in vivo (Lin et al., 2005). Because NF must assemble in 
stoichiometrically correct ratios, overexpressing NFL exclusively may cause issues in 
p190RhoGEF’s function and lead to aggregation of these p190RhoGEF-NFL complexes 
(Wong et al., 2000). Moreover, p190RhoGEF is seen to form punctate aggregates 
alongside NF aggregates in transgenic mtSOD1 mouse expressing the human G93A 
mutation. This linkage of p190RhoGEF with the induction of NF pathology and a motor 
neuron degeneration was of particular interest.  
In addition to its potential role in motor neuron degeneration, p190RhoGEF has also been 
shown to interact with focal adhesion kinase (FAK) and in this way modulate axonal 
branching and synapse formation in neurons (Zhai et al., 2003; Rico et al., 2004). This 
interaction may be a result of p190RhoGEF acting as a scaffold, where the pleckstrin 
homology domain of p190RhoGEF locates the protein to the cell membrane. At the 
membrane, p190RhoGEF interacts with FAK and brings other proteins together, such as 
Paxillin and integrin proteins, for signal transduction activity (Miller et al., 2013). 
Whether this function is preserved in human RGNEF is currently unknown. 
Though RGNEF and p190RhoGEF are homologues of each other, they may still differ 
from one another. Indeed, the lengths of the two proteins differ slightly: RGNEF is 1731 
amino acids long while p190RhoGEF is 1693 amino acids long (Droppelmann et al., 
2013) (Fig. 2). When comparing amino acid similarities between the two proteins, 80% 
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homology is obtained. The guanine exchange factor domain, shown to specifically 
activate RhoA in both RGNEF and p190RhoGEF, is particularly similar between the two 
proteins, showing 92% identity (van Horck et al., 2001; Droppelmann et al., 2013). 
Although this degree of homology would suggest identical functions, we have shown that 
while both p190RhoGEF and RGNEF can interact directly with NEFL mRNA, 
p190RhoGEF stabilizes the transcript while RGNEF destabilizes it (Canete-Soler et al., 
2001; Droppelmann et al., 2013). It is unclear how this difference between the two 
proteins affects their roles in ALS pathogenesis. However it does demonstrate that even 
with 80% identity, the two proteins are not the same and research performed in 
p190RhoGEF must be confirmed with experiments using RGNEF so that the results are 
more applicable in humans. 
While many studies have been performed regarding p190RhoGEF and NFL related motor 
neuron degeneration, there remains much to be explored for RGNEF. For example, 
though illustrations of p190RhoGEF show the existence of a leucine-rich domain and a 
cysteine-rich zinc binding domain, not much research has been performed on these 
domains (van Horck et al., 2001; Droppelmann et al., 2013).  In particular, the leucine-
rich domain of RGNEF is predicted to be located between amino acids 99 and 207. 
Traditionally, leucine-rich domains (or leucine-rich repeats) have been shown to mediate 
protein-protein interactions and have been shown to be important in cellular processes 
such as apoptosis and neural development (Inohara et al., 1999; Mutai et al., 2000). 
Interestingly, leucine-rich domains have been implicated in Parkinson’s disease. 
Specifically, mutations in Leucine-rich repeat kinase 2 (LRRK2) have been described as 
a major cause in both sporadic and familial cases of Parkinson’s disease (Paisan-Ruiz et 
al., 2004; Zimprich et al., 2004). However, when looking at this domain in RGNEF it is 
clear that the domain does not resemble classical leucine-rich domains. The amino acid 
sequence in this region of RGNEF lacks the typical LxxLxLxxNxL pattern (Kobe & 
Kajava, 2001). Nevertheless, this region is enriched with leucine amino acid residues 
(about 26.6% of the amino acids in this region are leucines) and its role in the protein 
should not be overlooked. 
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The cysteine-rich zinc binding domain of RGNEF is predicted to be located between 
amino acids 654 and 699. RGNEF’s domain here does resemble the typical zinc binding 
domain which is responsible for binding phospholipids such as diacylglycerol (DAG) or 
phorbol esters (Ono et al., 1989). Originally, this domain is utilized by protein kinase C 
(PKC) to locate itself to the cell membrane, bind DAG, and initiate signal cascades such 
as glycogen synthase kinase 3β (GSK-3 β) inhibition (Alkon, Sun, & Nelson, 2007). 
Though this may imply a scaffolding role of RGNEF for targets of PKC, no studies have 
been performed to examine the domain’s function. 
In addition to protein domains, RGNEF is also predicted to have many sites available for 
post-translational modifications. Indeed, RGNEF can be phosphorylated and 
SUMOylated at a myriad of sites throughout its length indicating that cells may modulate 
RGNEF activity in a vast number of ways (Droppelmann et al., 2014). In summary, more 
studies need to be performed to better characterize RGNEF’s physiological role so that its 
aggregation in ALS can be better understood. 
1.7 RGNEF’s potential role in stress response 
As discussed earlier, there are numerous reasons for motor neurons in ALS to be under 
significant oxidative stress (Shibata et al., 2001; Ferrante et al., 1997). This oxidative 
stress may arise from several sources, including malfunctioning mitochondria, 
surrounding inflammatory responses from microglia, and excitotoxicity (Simpson, Yen, 
& Appel, 2003). Whether or not aggregates of protein such as TDP-43 or FUS are also 
adding to this stress or acting as an innocent bystander remains to be seen. However, it 
has been found that TDP-43 is important in the assembly of stress granules, and that 
removing TDP-43 by RNA interference (RNAi) from cells reduces survivability in cells 
exposed to stress (Higashi et al., 2013; Aulas, Stabile, & Vande Velde, 2012). Similarly, 
FUS has been shown to colocalize with TIA-1 positive stress granules, and when 
knocked down using RNAi, a decrease in cell survivability in response to stress is 
observed (Sama et al., 2013). These studies suggest that, physiologically, TDP-43 and 
FUS play a protective role that may be lost when the two proteins aggregate in ALS 
motor neurons. 
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p190RhoGEF can also provide protection against stress, albeit using a different 
mechanism from SG formation. Wu and colleagues identified two domains on the C-
terminal region of p190RhoGEF shown to interact with either c-Jun N-terminal kinase 
(JNK) Interacting Protein 1 (JIP-1) or 14-3-3 proteins (Wu et al., 2003). When 
overexpressing either of these domains in a mouse neuronal cell line and then exposing 
these cells to chemical and heat shock stressors, cells overexpressing the domains 
experienced significantly less apoptosis compared to controls. This implies that, through 
an interaction with either JIP-1 or 14-3-3, p190RhoGEF can protect cells against stress. 
Taken together, the above would suggest that RGNEF can play a role in the cellular stress 
response. Like TDP-43 and FUS/TLS, RGNEF is an RNA binding protein whose 
expression is upregulated following axonal injury (Strong lab, unpublished observation); 
therefore RGNEF might be expected to participate in the stress response through the 
formation of SGs. Alternatively, because it is the human homologue of p190RhoGEF, 
RGNEF may also participate in the stress response through a JIP-1/14-3-3 mediated 
mechanism. In spite of the differences between RGNEF and p190RhoGEF in terms of 
destabilizing or stabilizing NEFL mRNA, respectively, both proteins nevertheless show 
80% homology and are demonstrated (Strong lab, unpublished observation) to be 
upregulated in response to sciatic nerve injury. Therefore, I would predict that RGNEF 
could have an equivalent function to p190RhoGEF in regards to its participation in the 
stress response.  Furthermore, the RhoA activation ability of RGNEF could indicate 
another mechanism involved in the cellular stress response. Indeed, the RhoA signaling 
pathway, through Akt activation, has been described to protect against cellular stress (Del 
Re, Miyamoto, & Brown, 2008). The purpose of my studies was to characterize RGNEF 
as a protein involved in the cellular stress response. 
1.8 Hypothesis 
My hypothesis is that RGNEF participates in the cellular stress response. This 
participation includes providing protection to cells stressed with oxidative, osmotic, or 
heat shock stress and this protection may occur through its guanine nucleotide exchange 
domain or its RNA binding domain. 
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Chapter 2 
2 Specific aims 
My first aim was to determine whether RGNEF expression in cells is protective against 
oxidative, osmotic, or heat shock stressors. To accomplish this, I used the human 
embryonic kidney 293 cell line containing large T antigen (HEK 293T cells). These cells 
were either stably transfected or transiently transfected and expressed RGNEF under a 
cytomegalovirus promoter. Cells were then exposed to either oxidative, osmotic, or heat 
shock stress and their resultant survival was examined using an MTT cell viability assay. 
Stably transfected, RGNEF overexpressing HEK 293T cells were compared to non-
transfected HEK 293T cells as a control. HEK 293T cells transfected with an empty 
vector plasmid were used as a control for all transiently transfected cells overexpressing 
an RGNEF construct.  
My second aim was to determine which domain of RGNEF was required for its 
protective effect. To do this, HEK 293T cells were transiently transfected with plasmid 
constructs containing different deletions of the RGNEF in which key functional domains 
(e.g. DH/PH domain, RNA binding domain, etc.) were removed. Cells were then 
subjected to the stresses defined in aim 1 and the resultant survival compared against both 
control transfections and transfections expressing the full length RGNEF construct.   
My third aim was to determine whether RGNEF is incorporated into RNA granules in 
response to cellular stress. To accomplish this, HEK 293T cells were either stably 
transfected or transiently transfected with full length RGNEF and then the cells subjected 
to stressors characterized in aim 1.  Fluorescence immunocytochemistry was used to label 
proteins marking RNA granules and RGNEF. Then, using, confocal microscopy, I 
examined whether RGNEF colocalized with RNA granules under a stress. 
2.1 Cell lines and transfections 
All experiments used HEK 293T cells. This cell line was chosen because they are 
amenable to transfection and because they express NEFL mRNA (Shaw, Morse, Ararat, 
& Graham, 2002). Cells were maintained in Dulbecco’s modified eagle’s medium 
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(Gibco, Life Technologies Inc., Burlington, Ontario) supplemented with 10% fetal bovine 
serum (Gibco) and kept in a water-jacketed, 37
o
C 5% CO2 incubator (Forma Scientific, 
Thermo Fisher Scientific, Ottawa, Ontario). 
HEK 293T cells stably transfected with the human RGNEF gene were created in our lab 
by Dr. Cristian Droppelmann using a full length myc-tagged RGNEF gene via the Jump-
in Fast Gateway Targeted Integration System (Invitrogen, Life Technologies Inc., 
Burlington, Ontario) (Droppelmann et al., 2013). These cells were convenient because 
they allowed us to observe RGNEF without needing to transiently transfect the cells 
beforehand. However, it may be possible that unforeseen variables would not be 
eliminated when comparing these stable-transfected cells against non-transfected cells. 
Thus, to better control for variables possibly introduced by a stable transfection, transient 
transfections in HEK 293T cells were also used to corroborate stable transfection results.  
For transient transfection, plasmid constructs of RGNEF using the plasmid backbone: 
pcDNA 3.1(+)/myc-His A were purified by Miniprep (Invitrogen) from transformed, 
chemically competent DH5α Escherichia coli (E. coli, Invitrogen). Different plasmid 
constructs were generated by inserting the gene of interest (variations on the full length 
cDNA of RGNEF) using restriction enzyme digests; more details are provided in the 
RGNEF constructs section below. The Miniprep was performed according to the 
manufacturer’s protocol. However the lysis time for the full length intact RGNEF 
construct (lysis buffer incubation step) was shortened to 3 minutes instead of the 
recommended 5 in order to reduce DNA fragmentation which we found to occur with the 
longer incubation period. DNA quality of the miniprepped DNA was assessed by running 
gel electrophoresis on a 1% agarose gel to compare purified plasmids against a control 
plasmid. GeneRuler 1kb Plus DNA Ladder (Thermo Fisher Scientific – Canada, Ottawa, 
Ontario) was used to observe the sizes of plasmids in 1% agarose gel. 
Transient transfections for this series of experiments were performed in 6-well plates 
using Lipofectamine 2000 (Invitrogen) according to the manufacturer’s protocol. HEK 
293T cells were be seeded at 200,000 cells per well in 6-well plates and allowed to grow 
48 hours to obtain a confluency of 70% in each well just before transfection. Cells were 
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transfected using Lipofectamine 2000, and 3.5 µg of plasmid DNA, according to 
manufacturer’s protocol. After overnight recovery, cells were seeded to a 96-well plate 
(12,000 cells per well), a 6-well plate (600,000 cells per well), or cover slips (600,000 
cells per well in a 6-well plate) and allowed 24 hours for recovery before MTT analysis, 
protein lysis, or immunocytochemistry protocols respectively. Trypan blue exclusion 
assay, introduced as a second measure of cell death, also required cells seeded to 6-well 
plates (600,000 cells per well). Figure 3 shows a graphical representation of this 
procedure. 
Note that while the cell seeding density for all MTT assay experiments were equal, the 
cell seeding density for trypan blue exclusion assays were slightly different. Seeding 
densities in 96-well plates for MTT assay were 50% confluent while seeding densities in 
6-well plates for trypan blue exclusion were 70% confluent. This discrepancy means that 
the survival results from the two experiments could be differentially affected by their 
differences in cell contact signaling (greater confluence observed leads to increased 
cellular contact and greater signaling). This is a limitation to be considered when 
comparing the MTT assay and trypan blue exclusion assay results. 
2.2 Western blot 
To ensure successful transfection by lipofectamine and to compare levels of protein 
expression across the different transfected RGNEF constructs, western blots were 
performed on protein lysates of transfected cells. 
Protein lysates from transfected HEK 293T cells were obtained by lysing cells on ice 
using a lysis buffer containing 1% Nonidet P-40 (NP-40), 2.5 mM 
phenylmethanesulfonyl fluoride (PMSF) in 90% ethanol, and “cOmplete protease 
inhibitor” (Hoffman-La Roche Ltd., Mississauga, Ontario) diluted in TBS. A cell scraper 
was used to mechanically scrape off remaining cells, and the resultant lysates were 
sonicated at output setting 40 to homogenize the lysate (Vibracell Sonicator; Sonics & 
Materials Inc., Newtown, Connecticut, USA). The homogenate was then centrifuged at 
4
o
C, 10,000 g for 10 minutes to pellet cell debris.  
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Figure 3:  Flowchart describing process of transfecting and seeding cells for use in 
experiments. 
  
Seed 200,000 HEK 293T cells to 6-well plates. Incubate for 48 hours. 
Transfect cells with plasmid constructs using Lipofectamine 2000.  
Allow cells to recover overnight. 
Seed transfected cells to 6-well plate at 600,000 cells per well (for western blot 
or immunocytochemistry or trypan blue exclusion assay) or seed transfected 
cells to 96-well plate at 12,000 cells per well (for MTT assay).  
Allow cells to grow and recover for 24 hours.   
Depending on purpose of the cells:  
Stress cells and analyze cell survival using MTT assay or trypan blue exclusion, 
Lyse cells using NP40 lysis buffer and store lysates within -20oC fridge for use 
in western blotting, or 
Fix cells using 4% paraformaldehyde and store cover slips within 4oC fridge for 
use in immunocytochemistry.  
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The supernatant containing protein was extracted and frozen at -20
o
C for storage. To 
quantify the concentration of protein within lysates, the Bio-Rad Dc protein assay was 
used according to the manufacturer’s protocol and colorimetric analysis was performed 
using a microplate reader (Microplate Reader Benchmark; Bio-Rad Laboratories Canada 
Ltd., Mississauga, Ontario) reading at 655 nm. Polyacrylamide gels were made at 10% to 
visualize RGNEF-myc constructs and an α-tubulin, or a GAPDH, protein loading control. 
All protein lysates were loaded at 40 µg per well based on protein concentrations 
determined from the Dc Assay. Lysates were also mixed with a protein loading buffer. 
The loading buffer contained 62.5 mM Tris base (pH to 6.8 using HCl), 2% SDS, 10% 
glycerol, 0.006 % Bromophenol blue, and 50% β-mercaptoethanol diluted in water. After 
mixing with buffer, lysates were denatured on a heat block (95
o
C) for 1 minute. Gels 
were run at constant 100 V until the dye front from the loading buffer reached the edge of 
the polyacrylamide gel. The running buffer contained 50 mM Tris base, 200 mM glycine, 
and 2 mM SDS diluted in deionized water. Gels were electrophoretically transferred to a 
nitrocellulose membrane at a constant 300 mA for 90 minutes. All equipment used for 
running and transferring gels was manufactured by Bio-Rad. A temporary ponceau-S red 
stain (Bio-Rad) was used on nitrocellulose membranes after protein transfer to confirm 
that the transfer was successful. Nitrocellulose was kept at 4
o
C overnight submerged in 
washing solution and held within a container with parafilm on top to prevent dehydration. 
The washing solution of pH 7.4 was made using 50 mM Tris base, 100 mM NaCl, and 
1% Tween20.  
Nitrocellulose membranes were blocked using a 5% milk blocking solution for non-
specific antibody binding, following which primary antibodies diluted in the 5% milk 
blocking solution were incubated with nitrocellulose film for 60 minutes at room 
temperature on an orbital shaker. Afterwards, the nitrocellulose membrane was washed 5 
times using 5% milk blocking solution, then incubated using secondary antibodies diluted 
in 5% milk blocking solution at room temperature. Table 3 lists the antibodies used and 
their dilutions.  
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Table 3:  Antibodies used for western blotting 
Name Species Dilution Manufacturer Secondary Antibody 
Myc  
(monoclonal) 
Mouse 1:5000 Cedarlane 
(Burlington, 
Ontario) 
Goat α-Mouse, linked to 
horseradish peroxidase  
(titre: 1:5000) (Bio-Rad) 
α-tubulin  
(polyclonal) 
Rabbit 1:2500 Abcam 
(Toronto, 
Ontario) 
Swine α-Rabbit linked to 
horseradish peroxidase  
(titre: 1:2500) (DAKO) 
GAPDH  
(polyclonal) 
Rabbit 1:2500 Abcam 
(Toronto, 
Ontario) 
Swine α-Rabbit linked to 
horseradish peroxidase  
(titre: 1:2500) (DAKO) 
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After secondary antibody incubation, the nitrocellulose membrane was washed 3 times 
using the washing buffer described previously. Western Lightning ECL reagent 
(PerkinElmer Woodbridge, Ontario), incubated on nitrocellulose for 2 minutes, was used 
to generate chemiluminescence signal from the washed nitrocellulose.  
Afterwards, a medical-grade film (Fuji Medical X-Ray Film; Christie InnoMed Inc., 
Mississauga, Ontario) was exposed and developed by a HOPE MicroMax X-Ray 
Processor (Hope X-Ray Products Inc., Warminster, Philadelphia, USA) in a dark room to 
obtain protein signals. Densitometry of the bands on exposed film was performed using 
ImageJ (version 1.48v; National Institutes of Health, USA) software on scanned x-ray 
films using a computer scanner (HP Scanjet G4010; Hewlett-Packard Canada Co., 
Mississauga, Ontario). 
2.3 RGNEF constructs 
To accomplish aim 2 it was necessary to generate different deletion constructs of RGNEF 
so that they could be transfected and analyzed in stressed cells, providing answers about 
the regions of RGNEF that are important in cellular stress response. Thus, in addition to 
full length RGNEF (1-1731 amino acid length), other constructs of RGNEF were 
transiently transfected into HEK 293T cells. These constructs were made by deleting 
parts of the full length protein by using PCR, by Pfu DNA polymerase (Thermo 
Scientific) utilizing primers (Table 4) designed for specific regions within the full length 
RGNEF cDNA. All constructs, including full length RGNEF, contain a myc-tag at the C-
terminal end of the protein so that transfected constructs can be easily detected using an 
anti-myc antibody. RGNEF constructs were inserted into the pcDNA 3.1(+)/myc-His A 
plasmid using restriction enzymes XhoI and KpnI (Invitrogen). Plasmids containing 
constructs were ligated at room temperature and transformed into chemically competent 
DH5α E. coli, after which the transformation was plated onto an agar plate containing the 
selective antibiotic ampicillin and incubated at 37
o
C overnight. Colonies were picked 
from the agar plate and grown in LB media overnight, following which they were 
harvested the next day using a Miniprep kit to obtain DNA plasmids for use in 
subsequent transfections.  
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Table 4:  Primers used in PCR to generate different RGNEF constructs. 
Name Forward or 
reverse 
primer 
DNA sequence (5’ to 3’) 
RGNEF-
ΔDHΔPH 
Forward(1) ATTGGTACCATGGAGTTGAGCTGCAGCGAA 
 
Reverse(1) TAAGGAGGTGTTTGATGACATCCTTCTCCTGC 
 
Forward(2) 
 
TGTCATCAAACACCTCCTTATTAAACCTGACCCA 
Reverse(2) 
 
AGACTCGAGCACCTTGAGGTCTACTTGATGTT 
RGNEF-
ΔCOOH 
Forward ATTGGTACCATGGAGTTGAGCTGCAGCGAA 
 
Reverse CAACTGGAGGGGCTCTAGATGGACGTCCTC 
 
RGNEF-
ΔDHΔPH 
ΔCOOH 
Forward ATTGGTACCATGGAGTTGAGCTGCAGCGAA 
 
Reverse TTTCTCGAGTTTGATGACATCCTTCTCCTGCCTATTAC 
 
RGNEF- 
ΔNH2 
Forward ATAGGTACCATGAGACAGGATGTCATTTTTGAGCTA 
 
Reverse AGACTCGAGCACCTTGAGGTCTACTTGATGTT 
 
RGNEF-
ΔLΔDHΔPH 
ΔCOOH 
Forward ATAGGTACCATGATTCACTCATCGGAAACGCT 
 
Reverse TTTCTCGAGTTTGATGACATCCTTCTCCTGCCTATTAC 
 
RGNEF- 
ΔL 
Forward ATAGGTACCATGATTCACTCATCGGAAACGCT 
 
Reverse AGACTCGAGCACCTTGAGGTCTACTTGATGTT 
 
*Restriction enzyme sequences are underlined. XhoI = CTCGAG; KpnI = GGTACC. 
**RGNEF-ΔDHΔPH is a fusion protein made by using two sets of primers, and where 
reverse(1) and forward(2) exhibit complementary sequence overlap. 
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RGNEF-ΔDHΔPH (deletion of amino acids 850-1202 and amino acids 1614-1731, the 
latter deletion performed to account for differences in predicted RGNEF isoforms 
containing the RNA-binding domain; this construct would be predicted to be 
nonfunctional as a guanine exchange factor (GEF) given that the combination of 
the DH and PH domain constitutes the RhoA GEF domain (Zheng, 2001), thus 
making this construct devoid of RhoA activating capacity),  
RGNEF-ΔCOOH (deletion of amino acids 1257-1731; this construct would be predicted 
to be devoid of any RNA binding capacity but also microtubule binding capacity 
and FAK activity),  
RGNEF-ΔDHΔPHΔCOOH (deletion of amino acids 850-1731; this construct would be 
predicted to be devoid of both GEF activity and RNA binding capacity),  
RGNEF-ΔNH2 (deletion of amino acids 1-850 and amino acids 1614-1731, the latter 
deletion was performed for the same reasons as was described for RGNEF-
ΔDHΔPH; this construct would contain only GEF activity and RNA binding, but be 
devoid of both the leucine rich domain and the zinc binding domain), 
RGNEF-ΔLΔDHΔPHΔCOOH (deletion of amino acids 1-242 and amino acids 850-1731; 
this construct is identical to the RGNEF-ΔDHΔPHΔCOOH construct but lacks the 
leucine rich domain), and  
RGNEF-ΔL (deletion of amino acids 1-242; this construct is the full length RGNEF 
construct without the leucine rich domain).  
Note that both the RGNEF-ΔLΔDHΔPHΔCOOH and RGNEF-ΔL contain a deletion of 
greater size than the predicted putative leucine-rich domain in order to fully eliminate any 
leucine-rich domain functions. Figure 4 illustrates graphically the different constructs.  
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Figure 4:  Comparison of the different deletion constructs of RGNEF. The cDNA of 
these constructs were placed into a pcDNA 3.1(+)/myc-His A plasmid and transfected to 
cells so that it could be determined which domain of the RGNEF protein was important 
in the cellular stress response. 
L = Putative leucine-rich domain, Zn = Zinc-binding domain, DH = Dbl-homology 
domain, PH = Pleckstrin-homology domain, RBD = RNA-binding domain. 
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2.4 Stress conditions  
Three types of stress were used with HEK 293T cells: oxidative stress, osmotic stress and 
heat shock. These stressors were chosen to provide a diverse panel of stressors with 
which to analyze cell survival and for their ability to induce stress granules as reported in 
the literature (Kedersha & Anderson, 2007). To induce oxidative and osmotic stress, 
sodium arsenite and sorbitol were used, respectively (Sigma-Aldrich, Oakville, Ontario). 
To determine the optimum conditions for the induction of cell injury, both time course 
and dose-response studies were conducted using MTT assays to assess the differences in 
cell viability. These optimization studies are further described in the results section. 
The duration of exposure and the concentration of stressor were optimized using MTT 
experiments on either stable or transiently transfected HEK 293T cells. Based on these 
studies, performed  in part to answer the first aim of this thesis, we induced oxidative 
stress with 0.5 mM sodium arsenite for 1 hour (in DMEM with 10% FBS; Gibco) and 
osmotic stress with 400 mM sorbitol for 4 hours (in DMEM with 10% FBS; Gibco). 
These optimized conditions for stress induction were maintained and utilized in aims 2 
and 3. Note that for stress survival studies, all stressed cells were immediately analyzed 
by MTT assay and no recovery time was allotted after either oxidative or osmotic 
stressors. 
Heat shock was performed by placing cells into a water-jacketed, 5% CO2 cell incubator 
set to the temperature 42.5
o
C. Heat shock was induced by either shocking cells for 1, 2, 
or 3 hours and allowing 24 hours to recover, or by inducing sustained heat shock (24 hour 
exposure). 
2.5 Immunofluorescence and confocal microscopy 
In order to observe whether RGNEF associates, or colocalizes, with RNA granules under 
stress, immunofluorescence coupled with confocal microscopy was used to observe 
transfected HEK 293T cells after a stress.  
Cells were seeded at 600,000 per well to a 22 x 22 mm cover slip within a 6-well plate 
and allowed to grow overnight. Stressors were applied afterwards (as described in the 
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previous section) and then cover slips were washed once with PBS and then fixed in a 4% 
paraformaldehyde, PBS solution for 15 minutes followed by 0.2% Triton X-100 in PBS 
solution for 10 minutes to permeabilize cells. Afterwards, 50 mM ammonium chloride 
solution was added for 30 minutes to quench aldehyde groups, reducing background. 
Non-specific antibody interactions were reduced by incubating cover slips for 60 minutes 
with an 8% bovine serum albumin (BSA; Fisher Scientific Company, Ottawa, Ontario) in 
PBS solution at room temperature. Each primary antibody was diluted into the 8% BSA 
solution, as indicated in Table 5, and incubated with coverslips for 90 minutes at room 
temperature. Specifically, antibodies against c-myc were used to identify RGNEF 
constructs, which were myc-tagged at the C-terminus. Antibodies against TIA-1 and 
Staufen were used to detect stress granules and transport granules respectively (Kedersha 
et al., 2000; Ferrandon et al., 1997). After this incubation, cover slips were washed twice 
with PBS and then incubated for 60 minutes at room temperature with secondary 
antibody diluted in BSA solution, as described in Table 5. Fluorescent AlexaFluor® 
antibodies (Life Technologies) were used to visualize fluorescence in cells. Afterwards, a 
1 µg/mL Hoechst stain in PBS was applied for 10 minutes to visualize nuclei, and cover 
slips were then washed, first with PBS and then with deionized H2O, and left to dry 
overnight. After drying, cover slips were mounted to frosted glass microscope slides 
using a fluorescent mounting media (Dako Canada Inc., Burlington, Ontario). All cover 
slips were examined using a multi-photon confocal microscope (LSM 510 META; Carl 
Zeiss Canada Ltd., Toronto, ON) and AIM software (version 4.2; Carl Zeiss Canada 
Ltd.). 
2.6 Cell survival assays 
The MTT assay (Thiazol Blue Tetrazolium Bromide; Sigma-Aldrich), utilizing 96-well 
plates and a microplate reader (Bio-Rad), was performed to determine cell viability after 
stress. Each plate was divided in half where one half of the plate (6 wells) was left 
untreated and another half (6 wells) was treated with a stressor. MTT (1 mg/ml) was 
incubated with cells for 1 hour during the stress treatment, after which all liquid was 
removed from the wells using a 200 µL multi-channel pipettor.  
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Table 5:  Antibodies used in immunocytochemistry for confocal microscopy 
Name Species Titre Manufacturer Secondary Antiobdy 
 
c-Myc 
(monoclonal) 
 
Mouse 
 
1:250 
 
Cedarlane 
(Burlington, Ontario)  
Donkey or Goat α-
Mouse, 488 nm 
absorbance, Life 
Technologies  
(titre: 1:800) 
 
Staufen 
(polyclonal) 
 
Rabbit 
 
1:100 
 
Millipore (Canada) Ltd 
(Etobicoke, Ontario)  
Goat α-Rabbit, 555 
nm absorbance, Life 
Tecnologies  
(titre: 1:800) 
 
TIA-1 
(polyclonal) 
 
Goat 
 
1:100 
 
Biovision 
(Edmonton, Alberta)  
Donkey α-Goat, 546 
nm absorbance, Life 
Technologies  
(titre: 1:800) 
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To lyse cells and solubilize purple formazan crystals for detection by microplate reader, 
200 uL of 99% Dimethyl Sulfoxide (DMSO; VWR International, Mississauga, Ontario) 
was added to the empty wells in the 96-well plate. For each experimental condition, 6 
duplicate wells of that condition were prepared on the same plate to make the 
colorimetric measurement of each condition more robust. Colorimetric analysis was 
performed by the microplate reader at 570 nm with background absorbance referenced at 
655 nm.  
We also used the trypan blue (Gibco) exclusion assay as a second measure of cell death. 
Where the MTT assay is a measure of mitochondrial function by assaying mitochondrial 
dehydrogenase activity, the trypan blue assay shows the loss of cell membrane integrity 
and as a result dying cells stain blue (Hoskins, Meynell, & Sanders, 1956; Slater, Sawyer, 
& Straeuli, 1963). Cells were incubated for 1 minute with trypan blue (1/100, v/v), 
washed and then the ratio of live to total (live and dead) cells, or the “ratio of surviving 
cells” was determined by counting with a hemocytometer under a light microscope. This 
cell counting was performed by observing 4 squares (one square grid from each corner of 
the hemocytometer). 
The ratio of surviving cells was calculated per square and these 4 values were combined 
to calculate a mean and standard error of the mean for the specific condition. 
2.7 siRNA experiments 
To corroborate survival data from stably transfected cells, RNA interference, in the form 
of siRNA transfections, was used to knockdown RGNEF. All siRNA experiments used 
stably transfected, RGNEF overexpressing HEK 293T cells (RGNEF+) as previously 
described (Droppelmann et al., 2013). RGNEF+ cells were transfected, using 
lipofectamine 2000 (Invitrogen), with either a control siRNA (SASI_HS02_00315236; 
Sigma-Aldrich) or a siRNA against RGNEF (SASI_HS01_00264015; Sigma-Aldrich). It 
was noted that the siRNA transfections did not completely eliminate the expression of 
RGNEF from the RGNEF+ cells. To further lower expression of RGNEF in the RGNEF+ 
cells, a sequential transfection of siRNA was performed using both control siRNA and 
the siRNA against RGNEF. This transfection was performed 3 times, allowing for 48 
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hours of recovery after ending each transfection. Transfections of siRNA were ended by 
seeding the transfected cells to a new plate and this seeding was required to ensure cells 
did not become overconfluent. 
Western blot was used to determine the amounts of RGNEF knock down as a result of 
siRNA transfection. MTT assay was used to analyze the differences in survival between 
the two groups mentioned (control siRNA and siRNA against RGNEF) when those cells 
are stressed with either 0.5 mM arsenite for 1 hour or 400 mM sorbitol for 4 hours. Note 
that for the MTT assay experiments performed here, only one siRNA transfection was 
used to knock down RGNEF expression. This is because the additional sequential 
transfections of siRNA (either 2 or 3 sequential transfections) did not appear to lower 
RGNEF expression more than using just a single siRNA transfection. Also, this limited 
any additional stress that the siRNA transfection may have been causing. To examine 
whether the transfection of siRNA itself, in the absence of arsenite or sorbitol stress 
treatments, was leading to cell stress, a control transfection of lipofectamine 2000 without 
siRNA mixed into it was performed on RGNEF+ cells and compared to the stressed cells. 
2.8 Statistical analysis 
To interpret the results obtained from MTT survival assays, statistical analysis was 
required to analyze the raw data. The absorbance values obtained from the MTT assay in 
all experiments were transformed to represent a “Percent Survival” value using the 
following equation: 
 
 
“Stressed Cell Absorbance” is the mean absorbance value calculated for cells that have 
been exposed to a stress condition (e.g. arsenite). “Untreated Cell Absorbance” is the 
mean absorbance value for corresponding cells that have only had their media replaced. 
Both “Stressed Cell Absorbance” and “Untreated Cell Absorbance” represent the mean of 
6 duplicate wells on the same 96-well plate. As mentioned previously, 6 replicated wells 
were used to make the colorimetric analysis more robust. Each “Percent Survival” that 
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was calculated represented one independent experimental value for its corresponding 
condition (e.g. a “Percent Survival” value for HEK 293T cells transiently transfected with 
full length RGNEF treated with 400 mM sorbitol for 4 hours). These resultant “Percent 
Survival” values were then compared amongst each other.  
For example, a mean and standard error of the mean was calculated from five “Percent 
Survival” values obtained from five independent experiments performed for the 
condition: HEK 293T cells transiently transfected with full length RGNEF treated with 
400 mM sorbitol for 4 hours. To search for outliers within the “Percent Survival” data of 
each construct, “R software” using the Grubb’s test for outliers, contained within the 
“outliers” package, was used according to an online statistics handbook maintained by 
the National Institute of Standards and Technology (Filliben & Heckert, 2014). Grubb’s 
test for outliers generates a p-value based on a given dataset and we chose to reject either 
the highest or lowest value in the dataset if p < 0.05.  
All conditions were analyzed for significant differences between each other using either 
Student’s t-test when comparing two groups or one-way ANOVA when comparing more 
than two groups. When using one-way ANOVA, significance was defined as p < 0.05 as 
provided by the Fisher least significant difference (Fisher LSD) post-hoc test to reduce 
the occurrence of “Do Not Test” values generated by the statistical software. All 
statistical analyses, including line and bar graphs, were performed or generated using 
SigmaPlot 10.0 (Systat Software Inc., San Jose, California, USA) based on mean and 
standard error of the mean. 
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Chapter 3 
3 Experimental results 
3.1 Survival experiments in stably transfected cells 
To examine the effects of RGNEF on the stress response, I first examined a stably 
transfected HEK 293T cell line that overexpressed myc-tagged RGNEF (RGNEF-myc). 
Cells were exposed to either of an oxidative, osmotic, and heat shock stress. The 
concentrations for the stressors were chosen based on their reported ability to induce the 
formation of stress granules and a range of concentrations around this accepted value was 
then tested (Kedersha & Anderson, 2007). The cells were exposed over the course of 24 
hours following which cell survival was assayed using the MTT assay. The mean 
survival, with standard error of the mean, was plotted over time for stably transfected 
cells and for non-transfected HEK 293T cells (control).  A survival curve was fitted using 
non-linear regression.  
For all concentrations of arsenite and sorbitol, the stably transfected cells showed 
increased survival compared to non-transfected cells when comparing their respective 
curves (Fig. 5). When comparing different concentrations of stressors, 0.5 mM arsenite 
(Fig. 5B) showed the greatest difference between the curves suggesting that it would be 
easier to resolve the survival differences between control cells and cells overexpressing 
RGNEF. Though 200 mM sorbitol (Fig. 5D) showed the greatest difference between the 
curves, 400 mM sorbitol (Fig. 5E) was chosen to be the standard concentration used in 
the proceeding experiments. The two concentrations: 0.5 mM arsenite and 400 mM 
sorbitol, were chosen because of their smaller error bars in the data, the separation 
between the two curves (non-transfected cells and stably transfected cells), and because 
these concentrations  have been used in previously published studies examining cellular 
stress (Sama et al., 2013; Higashi et al., 2013). 
 
  
49 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5:  Survival over time of cells exposed to different oxidative and osmotic 
stress concentrations. (A-C) Graphs showing different concentrations of arsenite used to 
induce oxidative stress in cells. (D-F) Graphs showing different concentrations of sorbitol 
used to induce osmotic stress in cells. All graphs presented here had a curve generated by 
non-linear regression and fitted to data points plotted within the graph. In all graphs, the 
dotted line (representing cells overexpressing RGNEF) shows greater survival over the 
solid line (representing non-transfected HEK 293T cells). 
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Figure 6:  Survival over time of cells exposed to sustained or recovery heat shock 
protocols. (A) Graph showing the change in cell survival of cells exposed to a sustained 
level of heat shock of 42.5
o
C over time. (B) Graph showing the change in survival 
compared to an untreated condition of cells exposed to 1, 2 or 3 hours of heat shock at 
42.5
o
C then allowed 24 hours recovery. 
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For the experiments examining the effect of heat shock, two experimental paradigms 
were used (Fig. 6).  In the first, cells stably transfected with RGNEF or non-transfected 
cells were exposed to 42.5
o
C continuously over 24 hours. In the second, cells stably 
transfected with RGNEF or non-transfected cells were transiently exposed to heat shock 
at 42.5
o
C for intervals of 1,2, or 3 hours of 42.5
o
C and then allowed to recover for 24 
hours. At the 24 hour mark, cell survival was then assayed using the MTT assay. 
There appeared to be a dichotomy between cells continuously exposed to heat shock over 
24 hours and cells allowed to recover after their heat shock. In the continuously exposed 
condition (Fig. 6A), stably transfected cells showed greater survival than non-transfected 
cells when comparing the two curves. It should be noted that the data point at 2 hours of 
heat shock for non-transfected cells appears to strongly influence the non-transfected 
survival curve to show this difference. Conversely, in the recovery condition (Fig. 6B), 
stably transfected cells showed no difference in survival as the line graphs generated 
show overlapping curves. Because of these inconclusive results, the heat shock condition 
was not re-iterated in survival experiments involving transiently transfected cells. 
3.2 Survival experiments in transiently transfected cells 
To corroborate oxidative and osmotic stress results from the stably transfected cells, and 
in anticipation of using the various RGNEF constructs, transiently transfected cells were 
used in place of stably transfected and non-transfected cells. Transient transfection 
experiments were also used to better control for any hidden variables that may have been 
introduced by the stable transfection protocol as non-transfected cells are an imperfect 
control for stably transfected cells. Note that for the reasons described earlier, heat shock 
experiments were not performed on these cells. 
Cells transfected with RGNEF-myc plasmid demonstrated a greater survival following 
either 0.5 mM arsenite or 400 mM sorbitol as illustrated in figure 7A and 7B. This is 
most evident at the exposure times of 1 hour for 0.5 mM arsenite (p = 0.006) and 4 hours 
for 400 mM sorbitol (p = 0.043; Student’s t-test) and thus these stress conditions were 
chosen as the standard in later experiments. A western blot was performed to confirm 
expression of RGNEF-myc in transfected cells (Fig. 7C).  
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Figure 7:  Survival over time of transiently transfected cells exposed to arsenite or 
sorbitol stress. (A) Graph showing the change in cell survival of cells exposed to 0.5 
mM arsenite over time. (B) Graph showing the change in cell survival of cells exposed to 
400 mM sorbitol over time. Note that for (A) and (B), the asterisk shows p < 0.05 by 
Student’s t-test. (C) Western blot showing presence of RGNEF-myc in transfected cells. 
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3.3 Trypan blue assay 
The MTT assay relies on the reduction of 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide within the cell to provide a measure of cell viability. 
Because this reaction is reliant on mitochondrial activity, it is possible that the MTT 
assay may be showing decreases in cellular metabolism as opposed to cellular death 
(Slater et al., 1963). For this reason, a trypan blue exclusion assay was performed as an 
alternate measure of cell death to confirm that data from MTT assay is describing 
changes in cell viability (Hoskins et al., 1956). 
HEK 293T cells transiently transfected with either an empty vector or a plasmid 
containing RGNEF-myc were stressed by arsenite or sorbitol as previously described and 
trypan blue exclusion assay was performed immediately after. Cells that were transfected 
with an empty vector plasmid showed a significant reduction in survival between 
unstressed cells and cells stressed with 0.5 mM arsenite (p = 0.008) or with 400 mM 
sorbitol (p = 0.003). Conversely, cells that were transfected with RGNEF showed no 
significant differences in survival between unstressed and arsenite or sorbitol stressed 
cells (Fig. 8). Note that while there was no significant difference between the percent 
survival of empty vector cells and RGNEF transfected cells within their groups of stress 
conditions (untreated, arsenite, sorbitol), there was a significant difference in survival 
between stressed (arsenite or sorbitol) and untreated conditions for empty vector cells.. 
This result implies that RGNEF does provide protection against stress and agrees with the 
MTT assay results shown in Figure 7. Furthermore, it confirms that loss of cell viability 
observed with the MTT assay is reflective of cell death in response to either sorbitol or 
arsenite. 
3.4 RNA silencing experiments 
To further corroborate survival data from transient transfections of myc-tagged RGNEF, 
silencing RNA (siRNA) against RGNEF was transfected into stably transfected RGNEF-
myc overexpressing cells and stressed with 0.5 mM arsenite or 400 mM sorbitol at 1 and 
4 hours respectively.  
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Transfected 
plasmid 
Stress condition Mean percent 
survival 
ANOVA p-value 
against control 
Empty vector 0.5 mM arsenite,  
1 hour 
70.603 0.005 
400 mM sorbitol,  
4 hours 
67.795 0.001 
RGNEF 0.5 mM arsenite,  
1 hour 
78.331 0.194 
400 mM sorbitol,  
4 hours 
72.102 0.194 
Figure 8:  Survival of transiently transfected cells exposed to 0.5 mM arsenite or 400 
mM sorbitol stress measured using the trypan blue exclusion assay. (A) White bars 
show empty vector transfected cells, while grey bars show RGNEF-myc transfected cells. 
Stress was applied at 0.5 mM arsenite for 1 hour or 400 mM sorbitol for 4 hours. Using 
Student’s t-test, bars within either untreated, arsenite or sorbitol groups were not 
significantly different (N.S.) from each other in the same group. Asterisks denote p < 
0.05 when comparing untreated bars with arsenite or sorbitol bars within either empty 
vector or RGNEF groups. (B) Table showing mean percent survival and p-values for data 
shown in (A). Statistics were performed within empty vctor or RGNEF-myc data groups 
and used one-way ANOVA with Fisher LSD post-hoc test.  
B 
A 
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Figure 9:  Survival of stably transfected RGNEF-myc cells transfected with siRNA 
against RGNEF and exposed to arsenite or sorbitol stress. (A) Graph showing percent 
survival of cells stressed using 0.5 mM arsenite for 1 hour. (B) Graph showing percent 
survival of cells stressed using 400 mM sorbitol for 4 hours. Statistics by one-way 
ANOVA found no significant differences between groups in (A) or (B). (C) 
Representative western blot showing knockdown of RGNEF-myc from stably transfected 
cells. 1x, 2x, 3x describe the number of siRNA transfections sequentially performed on 
the cells to further decrease protein levels by knockdown, or as a corresponding control 
to these transfections. RGNEF+ stands for stably transfected, RGNEF overexpressing 
HEK 293T cells. HEK293T stands for non-transfected, HEK 293T cells. (D) 
Densitometry graph showing the differences in intensity (as a ratio of corresponding 
alpha-tubulin intensity) of RGNEF bands shown in (C). 
C D 
B A 
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As a control, a silencing RNA shown not to affect RGNEF-myc protein levels was 
transfected to stably transfected RGNEF-myc cells (Fig. 9A). Note that while the 
knockdown of RGNEF-myc by siRNA was successful, some expression of RGNEF-myc 
remains in the stably transfected cells. Upon analysis, there was no significant difference 
between stably transfected cells that were exposed to lipofectamine 2000 only (no siRNA 
transfected; used to control for the stress of the siRNA transfection), stably transfected 
cells transfected with control siRNA, or stably transfected cells transfected with siRNA 
against RGNEF-myc in either arsenite (p = 0.052) or sorbitol (p = 0.147) stressed cells 
(Fig. 9B).  
These results show that the siRNA transfection itself appears to have an impact on cell 
survival (cells that were only transfected with lipofectamine showed greater survival than 
either siRNA transfected cells), albeit an insignificant one. Also, the western blot and 
graph shown in Figure 9C and 9D respectively show that the sequential siRNA 
transfection do not appear to be able to abolish RGNEF-myc expression by the stably 
transfected cells. In fact, after 3 sequential transfections there appears to be an increase in 
RGNEF-myc expression (for both control siRNA and siRNA transfections). This could 
indicate that the sequential transfection presents a significant stress, leading to an 
upregulation of RGNEF within the cells (agreeing with unpublished data from our lab 
pertaining to the upregulation of RGNEF in transected sciatic nerves of rodents). 
 Interestingly, there appears to be a trend in the data where cells treated with siRNA 
against RGNEF-myc had increased survival under arsenite or sorbitol stress. This trend 
may indicate that siRNA against RGNEF is non-specific, potentially targeting other 
proteins endogenous to the cell and affecting cell signaling in a manner that is subtly 
beneficial under stress conditions. However, this possibility was not investigated and, as 
mentioned, the difference between the three groups shown in Figure 9A and B is not 
significant by one-way ANOVA. When analyzing the control siRNA and siRNA groups 
alone, the two were insignificant by Student’s t-test (arsenite: p = 0.103; sorbitol: p = 
0.169). 
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3.5 Survival experiments examining different constructs of 
RGNEF 
In order to determine which domain of RGNEF was providing the stress protection in 
response to either arsenite or sorbitol, we constructed a number of RGNEF constructs 
using the pcDNA 3.1 myc His A plasmid such that every construct was myc-tagged at 
their C-terminus. Each deletion removed at least one domain of RGNEF as previously 
described.  All experiments were performed using the protocol described previously for 
the transient transfections. The MTT assay was used to determine cell survival after 
exposure to either 0.5 mM arsenite (Fig. 10A) or 400 mM sorbitol (Fig. 10B) stress, for 1 
and 4 hours, respectively.  We used western blotting to confirm the expression of myc-
tagged constructs in transfected cells. 
In both arsenite (p < 0.001) and sorbitol (p < 0.001) stresses, full length RGNEF 
conferred a significant improvement in cell survival when compared to empty vector 
control. When the guanine exchange domain comprised of both Dbl homology and 
Pleckstrin homology domains of RGNEF was deleted (RGNEF-ΔDHΔPH), a significant 
difference between cells overexpressing this construct and empty vector cells was still 
observed in arsenite (p = 0.009) and sorbitol (p = 0.018) stress. Similarly, cells 
overexpressing a construct of RGNEF where the RNA-binding domain was deleted 
(RGNEF-ΔCOOH) exhibited greater survival compared to empty vector in both arsenite 
(p = 0.006) and sorbitol (p = 0.034) stresses. 
When observing cells overexpressing RGNEF with its C-terminal half deleted (RGNEF-
ΔDHΔPHΔCOOH), there continued to be a greater survival compared to empty vector 
transfected cells following either arsenite (p = 0.003) or sorbitol (p = 0.018) exposure. 
Conversely, cells overexpressing RGNEF with its N-terminal half deleted (RGNEF- 
ΔNH2) only showed significantly greater survival than empty vector cells in sorbitol 
stress (p = 0.047). When treated with arsenite, there was no significant difference (p = 
0.083) between empty vector cells and RGNEF-ΔNH2 cells.  
These results were unexpected and suggested that neither the GEF domain nor RNA 
binding domain, alone or in combination, conferred the protective benefit of RGNEF 
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against either arsenite or sorbitol stress.  Indeed, the results suggest that the N-terminal 
region of RGNEF is critical to conferring this protection.  
To focus further on the N-terminal domain of RGNEF which contains both the leucine 
rich domain and the zinc binding domain, cells were transfected with a construct that 
contained only the N-terminal domain of RGNEF but in which the leucine rich domain 
was deleted (RGNEF-ΔLΔDHΔPHΔCOOH). Cells overexpressing this construct showed 
no significant difference in survival between empty vector in either arsenite (p = 0.152) 
or sorbitol (p = 0.592) stress. This is not entirely unexpected however as the construct 
now lacks virtually all of the domains that could confer any effect, and indeed, bears little 
resemblance to RGNEF. To overcome this, we designed a construct in which full length 
RGNEF was expressed but with the leucine rich domain deleted (RGNEF-ΔL). Using this 
construct, RGNEF-L transfected cells again showed significantly greater survival 
compared to empty vector cells in arsenite (p = 0.002), but not sorbitol (p = 0.301) stress. 
This suggests that the leucine rich domain may be of importance in providing the 
cytoprotective effect of RGNEF, but not under all conditions of stress. 
In order to ensure that the observed differences were not a reflection of differing levels of 
protein expression, we examined the level of protein expression for each construct using 
Western blotting (Fig. 11A).  Three independent protein lysates were analyzed for each 
construct, and the resulting densitometry results plotted (Fig. 11B).  
Densitometries for each construct were obtained by ImageJ software and calculated as a 
value relative to a corresponding α-tubulin loading control to control for any errors in 
loading of the polyacrylamide gel.  Using a one-way ANOVA analysis, we found no 
significant differences in protein expression between any of the constructs (p = 0.143). 
Transfection efficiencies were also analyzed for transfected plasmids using 
immunofluorescence microscopy (Fig. 11C). The efficiency is expressed as a ratio of 
green cells, denoting a transfected cell, to blue cells, denoting a general cell nucleus (i.e. 
transfected cells : total cells).  
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Figure 10:  Survival over time of cells transiently transfected with different 
constructs of RGNEF and exposed to arsenite or sorbitol stress. (A) Graph showing 
the percent survival of cells exposed to 0.5 mM arsenite for 1 hour. (B) Graph showing 
the percent survival of cells exposed to 400 mM sorbitol for 4 hours. Significance was 
determined as p < 0.05 and calculated by one-way ANOVA with the Fisher LSD post-
hoc test. (C) Legend of the different constructs shown, as bars, in graphs (A) and (B).  
  
A B 
C 
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Upon statistical analysis by one-way ANOVA with the Fisher LSD post-hoc test, there 
was a significant difference found for only two constructs: RGNEF-COOH and 
RGNEF-∆DH∆PH∆COOH. The other 5 constructs did not differ significantly from each 
other. 
RGNEF-∆COOH had significantly lower transfection efficiencies compared to full length 
RGNEF (p = 0.001), RGNEF-∆DH∆PH (p = 0.031), RGNEF-∆NH2 (p = 0.004), 
RGNEF-∆L∆DH∆PH∆COOH (p = 0.003), and RGNEF-∆L (p = 0.047). RGNEF-
∆DH∆PH∆COOH only had significantly lower transfection efficiencies compared to full 
length RGNEF (p = 0.043). It should be noted that survival benefit continues to be 
evident for both RGNEF-∆COOH and RGNEF-∆DH∆PH∆COOH in spite of their 
significantly lower transfection efficiency. Moreover, the transfection efficiency of 
constructs that do not show survival benefit, such as RGNEF-∆L∆DH∆PH∆COOH, 
shows similar efficiencies to constructs that do show survival benefit, such as RGNEF. 
Referring back to the protocol used for transient transfections, a constant of 3.5 µg of 
plasmid DNA was used in all transient transfection experiments. This means that the 
amount of plasmid DNA transfected was not normalized by molar concentration. Where 
constructs were larger and had a greater molar mass, less moles of the larger construct 
DNA would be transfected than constructs that were smaller and had a lower molar mass. 
This effect appears to be present in Figure 11B where the amount of protein expression 
observed for RGNEF-∆L∆DH∆PH∆COOH is much greater than the amount for RGNEF-
∆COOH. Consequently, this may have also affected the effiency of transfection, though 
again the constructs that had significantly lower transfection efficiencies continued to 
demonstrate survival benefit. It may follow then that the amount of survival observed in 
Figure 10 is underestimated for the two constructs: RGNEF-∆COOH and RGNEF-
∆DH∆PH∆COOH.  
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Figure 11:  Confirming efficiencies of transfections of different RGNEF constructs 
by western blot and immunofluorescence microscopy. (A) A representative, composite 
western blot showing the protein signals for different, myc-tagged RGNEF constructs. 
(B) Comparison of densitometries of western blots for different RGNEF constructs. By 
one-way ANOVA there is no significant difference between these values (p = 0.143). (C) 
Transfection efficiencies as observed by immunofluorescence microscopy and 
represented as a percentage of transfected cells vs. total cells. Significant difference 
determined by one-way ANOVA and Fisher LSD post-hoc test. (D) Legend showing 
constructs described in (B) and (C) 
A B 
C 
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In summary, this set of experiments suggests that RGNEF expression confers a survival 
benefit in the face of two different cellular stresses: 0.5 mM arsenite and 400 mM 
sorbitol.  The studies further suggest that this effect, independent of either the GEF or 
RNA binding domains, differs somewhat based on the nature of the cellular stress.  In the 
next section, given the importance of the N-terminus domain to the survival benefit and 
given the presence of both a leucine rich domain and Zn binding domain which would be 
predicted to confer both protein interaction capacity and stability, we examined whether 
the cytoprotective effect of RGNEF is mediated through its incorporation into stress 
granules. 
3.6 RNA granules and RGNEF localization under stress 
To determine whether integration into stress granules was the mechanism by which 
RGNEF was providing protection against stress, confocal microscopy was used to 
observe the subcellular localization of myc-tagged RGNEF and TIA-1 protein when 
exposed to 0.5 mM arsenite for 1 hour or 400 mM sorbitol for 4 hours. These 
experiments used stably transfected HEK 293T cells overexpressing RGNEF-myc. We 
observed that granular formations of RGNEF-myc did not colocalize with TIA-1 stress 
granules in either the arsenite or sorbitol stresses (Fig. 12). This makes stress granule 
formation an unlikely mechanism by which RGNEF was protecting against stress. 
Transport granules were also examined in stressed, stably transfected RGNEF-myc 
overexpressing cells to observe the relationship between transport granule localization 
and RGNEF granule localization during stress. We observed that staufen-positive 
transport granules occasionally colocalized with RGNEF-myc granules under arsenite or 
sorbitol stresses (Fig. 13). This implies that the transport of RGNEF may be important 
under stress conditions. Figure 14 shows a close-up comparison between stress granules 
and transport granules forming in RGNEF overexpressing cells. Notice that the 
colocalizing transport granules are yellow (overlap of red immunolabeled Staufen and 
green immunolabeled RGNEF-myc) while the stress granules are red (immunolabeled 
TIA-1) and separate from the green (immunolabeled RGNEF-myc). 
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Figure 12:  Localization of RGNEF-myc and TIA-1 stress granules formed when 
stably transfected RGNEF-myc cells are exposed to arsenite or sorbitol stress. The 
top row shows an unstressed control to compare the different localizations of RGNEF-
myc and TIA-1 when exposed to arsenite or sorbitol stress. TIA-1 forms large granular 
structures in the cell in response to either arsenite or sorbitol. These granules do not 
colocalize with RGNEF-myc in either arsenite or sorbitol stress. Scale bars represent 10 
µm. 
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Figure 13:  Localization of RGNEF-myc and staufen transport granules formed 
when stably transfected RGNEF-myc cells are exposed to arsenite or sorbitol stress. 
The top row shows an unstressed control to compare the localizations of RGNEF-myc 
and staufen when exposed to arsenite or sorbitol stress. Staufen forms granular structures 
whether or not the cells are stressed. These granules occasionally colocalize with 
RGNEF-myc in either arsenite or sorbitol stress and are shown with arrowheads. Arrows 
point to colocalizing granules. Scale bars represent 10 µm. 
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Figure 14:  Comparison of stress granules and transport granules. The top two 
pictures represent stress granules and are immunolabeled red for TIA-1, green for 
RGNEF-myc. The bottom two pictures represent transport granules and are 
immunolabeled red for Staufen, green for RGNEF-myc. Scale bars represent 10 µm. 
Colocalization is indicated by the white arrowheads. Notice that the colocalized transport 
granules are yellow while the stress granules, which do not colocalize, are red. 
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Chapter 4 
4 Discussion 
4.1 RGNEF protects against stress 
In both stably transfected and transiently transfected RGNEF overexpressing HEK 293T 
cells, we found that cells overexpressing RGNEF showed greater survival than the 
controls when exposed to 0.5 mM arsenite or 400 mM sorbitol stress. Overall, these 
results are consistent with the literature in that RNA-binding proteins that have been 
observed to form NCIs within spinal motor neurons of ALS are also described to be 
involved in the neuronal response to stress, including TDP-43, FUS, and angiogenin 
(Higashi et al., 2013; Sama et al., 2013; Subramanian et al., 2008). While it may be 
argued that the protection conferred by RGNEF is somewhat small (about 15% survival 
benefit in both 0.5 mM arsenite and 400 mM sorbitol stress), it is nevertheless significant 
in the context of ALS where several of these cytoprotective, RNA-binding proteins may 
be colocalized within the same NCIs within  motor neurons (Keller et al., 2012).  Thus, 
these small survival benefits that are lost may eventually act collectively to manifest as 
catastrophic failure of the motor neuron’s stress response resulting in cell death. 
It should be noted that in contrast to oxidative and osmotic stress, heat shock stress in 
stable transfection experiments produced mixed results. When applying a sustained heat 
shock of 42.5
o
C, stably transfected RGNEF cells (RGNEF+) showed a non-linear 
regression curve that was greater and separated from the non-transfected HEK 293T 
(293T) cell curve indicating that RGNEF has protective effects against heat shock. 
However, when performing heat shock recovery experiments, there were no differences 
between the survival of RGNEF+ cells and 293T cells exposed to 1, 2, or 3 hours of 
42.5
o
C heat shock and allowed 24 hours recovery. This discrepancy in results is 
surprising, though the difference between the curves observed for sustained heat shock 
may be explained by the large decrease in 293T cell survival seen at 2 hours of heat 
shock pointing to a possible outlier in the data. These results differ from a previous study 
describing p190RhoGEF providing anti-apoptotic effects against heat shock stress in 
mouse neuroblastoma Neuro2A cells (Wu et al., 2003). However, we have shown that 
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RGNEF functions differently from p190RhoGEF despite extensive sequence homology 
(Droppelmann et al., 2013). My observations illustrate another example of the functional 
differences between RGNEF and p190RhoGEF. In addition, HEK293T cells exhibit a 
constitutive transcription of the heat shock protein 70 which may provide the cells with 
an intrinsic resistance to heat shock stress and mask the protection benefit provided by 
RGNEF (Kao & Nevins, 1983). Future experiments should utilize a different cell line 
such as HeLa cells to account for this.  
When using siRNA transfection to attenuate the overexpression of RGNEF in stably 
transfected RGNEF+ cells, we observed no statistically significant difference in cell 
survival for either oxidative or osmotic stress. There is however a trend in favour of 
enhanced survival even in the presence of siRNA to RGNEF. Because the expression of 
RGNEF-myc is not completely eliminated (Fig. 9C), we cannot rule out the possibility 
that even in small amounts RGNEF can provide some degree of protection against the 
two stressors. In future studies, this issue could be addressed by using a cell line that 
shows endogenous expression of RGNEF and siRNA methodologies so that the 
overexpression of RGNEF itself is not affecting cellular behavior in an unforeseen 
manner. Indeed, when referring to previous stress protection studies involving TDP-43 
and FUS, the proteins are endogenously expressed by the cell line being examined and 
the siRNA used to attenuate this endogenous expression leads to decreased survival of 
the stressed cells (Higashi et al., 2013; Sama et al., 2013). 
4.2 N-terminal portion of RGNEF is important for its stress 
protection 
In order to determine the portion of RGNEF that is most important for providing 
protection against oxidative and osmotic stress (0.5 mM arsenite and 400 mM sorbitol 
respectively), different deletions of the protein were performed and expressed in stressed 
cells (Fig. 15). We first examined the significance of the RNA-binding domain by using a 
construct of RGNEF with its RNA-binding domain deleted: RGNEF-ΔCOOH. After 
removing the RNA-binding domain from RGNEF, cells continued to exhibit significantly 
greater levels of survival when compared to empty vector control (0.5 mM arsenite, p = 
0.006; 400 mM sorbitol, p = 0.026). These results show that the protective effects of 
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RGNEF could be retained in the absence of its RNA-binding domain for oxidative or 
osmotic stress protection.  Moreover, these results suggest that stress granule formation is 
not the mechanism by which full length RGNEF provides stress protection. Thus we 
looked at the RhoA activating domain of RGNEF next, which is composed of the Dbl 
homology (DH) and Pleckstrin homology (PH) domains. 
Our construct RGNEF-ΔDHΔPH was examined in stressed cells and, similar to RGNEF-
ΔCOOH, showed significantly greater survival compared to empty vector control 
(oxidative, p = 0.009; osmotic, p = 0.013). These results show that the DH and PH 
domains are not critical for the protection provided by full length RGNEF and suggest 
that RhoA activation is not the mechanism by which full length RGNEF protects cells 
from stress. Regarding RhoA’s role in protection, there is literature supporting both an 
apoptotic role (Al-Gayyar et al., 2013) and a protective role (Abe et al., 2014) of RhoA. 
This dichotomy appears to be related to the duration of RhoA activation and the 
subsequent pathway this activation leads to. One study has shown that less chronic 
activation of RhoA in rat cardiomyocytes activates a pathway involving focal adhesion 
kinase and culminating in cytoskeletal reorganization of the cell along with anti-apoptotic 
effects mediated by Akt (Del Re et al., 2008). Though this pathway may be linked to 
RGNEF’s protective function, especially due to RGNEF’s implied and p190RhoGEF’s 
proven involvement in the RhoA-FAK pathway, it is difficult to determine whether it is 
the mechanism by which the protein’s stress protection occurs (Miller et al., 2013). 
Indeed the protection observed in the absence of the DH and PH domains suggests that 
this RhoA-FAK pathway is not involved in cytoprotection. Nevertheless, future 
experiments should determine whether RGNEF’s effects on RhoA and FAK are retained 
in the absence of these domains. 
As the deletion of the RNA-binding domain (RGNEF-ΔCOOH) and the deletion of the 
DH-PH domains (RGNEF-ΔDHΔPH) continued to demonstrate a protective effect 
against stress compared to empty vector controls, we decided to divide the RGNEF 
protein into two parts: an N-terminal half (RGNEF-ΔDHΔPHΔCOOH) and a C-terminal 
half (RGNEF-ΔNH2).  
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Figure 15:  Review of deletion constructs of RGNEF used in experiments.  
L = Putative leucine-rich domain, Zn = Zinc-binding domain, DH = Dbl-homology 
domain, PH = Pleckstrin-homology domain, RBD = RNA-binding domain. 
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The N-terminal RGNEF-ΔDHΔPHΔCOOH contained neither the RNA-binding domain 
nor the GEF domain and was created to determine the combined importance of those two 
functional domains in stress protection. Conversely, the C-terminal RGNEF-ΔNH2 
contained only the RNA-binding domain and the GEF domain and was created to 
determine the importance of the largely unexplored N-terminal region of RGNEF in 
stress protection. The N-terminal protein RGNEF-ΔDHΔPHΔCOOH demonstrated 
significant increase in survival over empty vector controls in both oxidative (p = 0.002) 
and osmotic (p = 0.012) stress, whereas the C-terminal protein RGNEF-ΔNH2 only 
showed significant increase over empty vector controls in osmotic stress (p = 0.036). 
These results suggest that the N-terminal region of the RGNEF protein is more diverse in 
its protective function than the C-terminal RNA-binding domain and DH-PH domains.  
However, because both N-terminal RGNEF-ΔDHΔPHΔCOOH and C-terminal RGNEF-
ΔNH2 show significantly greater survival under osmotic stress it appears that there are 
regions within both portions of the RGNEF protein that can provide protection.  
After establishing that the N-terminal region of the RGNEF protein is important in both 
oxidative and osmotic stress, we decided to further explore the domains located in the N-
terminal region, specifically the putative leucine-rich domain. We began by deleting the 
putative leucine-rich domain from the N-terminal region, creating an RGNEF-
ΔLΔDHΔPHΔCOOH protein. The resulting protein showed no significant differences in 
survival when compared to an empty vector control under oxidative (p = 0.149) or 
osmotic (p = 0.655) stress. However, as this protein with its many deletions differed 
greatly in comparison to the full length RGNEF, we decided to make a deletion of the 
putative leucine-rich domain from the full length RGNEF, creating an RGNEF-ΔL 
protein. RGNEF-ΔL showed significantly greater survival under oxidative stress  
(p = 0.002), but not under osmotic stress (p = 0.265) when compared to an empty vector 
control.  
This loss of protection against an osmotic stress following deletion of the leucine rich 
domain greatly was unexpected given our prior observation that cytoprotection had been 
maintained for both osmotic and oxidative stress using either of the N-terminal RGNEF-
ΔDHΔPHΔCOOH or C-terminal RGNEF-ΔNH2 proteins. This could mean that 
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separation of the protein into an N-terminal and C-terminal half had unforeseen 
consequences on RGNEF’s cellular activity leading to the activation of signaling 
pathways distinct from those that the full length RGNEF normally participates in. Further 
study focused on characterizing both the protein binding partners of full length RGNEF 
and those of the different RGNEF constructs will be of assistance in answering this 
question. Also, because the leucine-rich domain of RGNEF is dissimilar compared to 
previously published articles describing leucine-rich domains, it is difficult to predict the 
domain’s function at this time. It is reasonable to assume that the domain is important in 
facilitating a protein-protein interaction, not only because conventional leucine-rich 
domains do so, but also because an ankyrin-repeat domain is embedded within this 
putative leucine rich domain (locus: NP_001073948; as described by NIH’s Protein 
database). These protein-protein interactions may then facilitate a cell signaling pathway 
that prevents apoptosis leading to stress protection in cells. Indeed, some proteins 
containing leucine-rich domains have been shown to be protective against apoptosis, such 
as LRRK2 (Chuang, Lu, Wang, & Chang, 2014). 
Taking the results from these deletion constructs as a whole, an interesting observation 
arises between the C-terminal half of RGNEF, RGNEF-ΔNH2, and the deletion of the 
leucine-rich region from the full length of RGNEF, RGNEF-ΔL. Where RGNEF-ΔNH2 
protects against sorbitol and not arsenite, RGNEF-ΔL instead protects against arsenite 
and not sorbitol. This is unexpected because RGNEF-ΔL possesses the same domains 
that RGNEF-ΔNH2 contains and would naturally be predicted to similarly protect against 
sorbitol. As mentioned previously, both the N-terminal region and C-terminal region of 
RGNEF may contain domains that can protect against cellular stress. The C-terminal 
region contains the GEF domain and RNA-binding domain, which may provide 
protection through, respectively, RhoA activation or interactions with JIP-1 and 14-3-3 as 
observed in the mouse homologue p190RhoGEF (Del Re et al., 2008; Wu et al., 2003). 
The N-terminal region contains the leucine-rich domain which may facilitate protein-
protein interactions leading to stress protection (Chuang et al., 2014). Whether or not 
these domains are active could depend upon protein folding of RGNEF, as shown in 
figure 16.  
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Figure 16:  A proposed model for the folding of RGNEF. Notice that the leucine-rich 
domain of RGNEF partly obscures the C-terminal region and therefore may be regulating 
the behavior of those domains in the protein. Alternatively, the C-terminal region could 
also play a regulatory role on the leucine-rich domain, affecting what protein binding 
partners can interact with it. This figure is not to scale with the RGNEF protein. 
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In the observation mentioned previously between RGNEF-ΔNH2 and RGNEF-ΔL, the 
protective effects may differ because of a potential regulatory role of the leucine-rich 
domain which inhibits the stress protection provided by the C-terminal region of RGNEF. 
Post-translational modifications to the protein, including phosphorylation and 
SUMOylation, could also be differentially regulated in these protein deletion constructs, 
leading to altered functionality of RGNEF protein. Indeed, more studies are needed to 
further explore the complex structure of RGNEF and the stress protective potential of its 
many domains. 
4.3 RGNEF localizes to transport granules under stress 
Previous studies have implicated RNA-binding proteins involved in ALS, specifically 
TDP-43 and FUS, as having stress protective properties through a mechanism of stress 
granule formation (Higashi et al., 2013; Sama et al., 2013). For example, TDP-43 is 
involved in the formation of stress granules and its knockdown by RNA interference 
decreases the survival of stressed cells (Aulas et al., 2012). Although RGNEF is similarly 
an RNA-binding protein with a role in the stress response, our results show that it does 
not colocalize with stress granules following either oxidative or osmotic stress. This 
result agrees with our observation that cells expressing RGNEF without its RNA-binding 
domain (RGNEF-∆COOH) still exhibit protection against arsenite or sorbitol stress 
compared to controls. However, this contrasts with the previously described studies 
where TDP-43 and FUS have been shown to colocalize with stress granules. Instead, our 
results suggest that RGNEF does not protect cells through a mechanism of stress granule 
formation. It should be noted, however, that our methodology involves fixation of the 
cells which may affect the protein dynamics within the cell. Also, because only one time 
point was examined by confocal microscopy, it is possible that RGNEF associates with 
stress granules at a time earlier or later than we expected. To solve these questions, future 
experiments should examine a greater number of time points. Also, the localization of 
endogenous TDP-43 or FUS under a stress should be examined and used as a positive 
experimental control to observe whether the stress protocol and the 
immunocytochemistry protocol are able to visualize the expected colocalization of TDP-
43 or FUS in stress granules. Furthermore, experiments utilizing live cell imaging should 
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be performed so that the protein dynamics of RGNEF and stress granules may be 
observed. 
Because RGNEF is an RNA-binding protein, and because it was not found to associate 
with stress granules, we examined whether RGNEF would colocalize with transport 
granules. Under either arsenite or sorbitol stress, we observed that RGNEF would 
occasionally colocalize with transport granules. This colocalization suggests that 
RGNEF’s protective mechanism involves transporting mRNA, or perhaps being 
transported itself, to specific locations within a cell during a stress. Alternatively, 
RGNEF may not be participating in RNA transport at all and may instead be involved in 
a process called staufen-mediated mRNA decay (Kim, Furic, Desgroseillers, & Maquat, 
2005). Interestingly, staufen-mediated mRNA decay appears to agree with previous 
studies showing that RGNEF can destabilize NEFL mRNAs in cells. In contrast to 
transport granules, the protective mechanism of RGNEF in this case may involve the 
degradation of transcripts selected through Staufen binding to specific mRNAs. 
RGNEF’s colocalization with Staufen may also indicate a pre-pathological aggregation of 
the protein as a result of stress. Although this mechanism of aggregate formation has only 
been suggested in a stress granule pathway (Wolozin, 2012), it may be possible to 
achieve a similar pathology through a transport granule pathway. To determine between 
these three possibilities: transport granule, staufen-mediated decay, or pre-pathological 
aggregate, future experiments should utilize live-cell imaging so that the protein 
dynamics of RGNEF can be monitored, specifically its movement or aggregation within 
cells. In addition, MS2-tagged mRNA targets of Staufen, in combination with RGNEF 
knockdown, may reveal whether RGNEF affects the process of staufen-mediated decay 
(Kim et al., 2005). 
4.4 Conclusion and future directions 
My hypothesis was that RGNEF participates in the cellular stress response. By 
participating in this stress response, we considered that RGNEF would behave similar to 
other RNA-binding proteins involved in ALS, or that it would do so through its role in 
the RhoA signaling pathway. Based on our results, I have shown that RGNEF is 
protective against oxidative or osmotic stress induced through 0.5 mM arsenite or 400 
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mM sorbitol respectively. However, unlike other RNA-binding protein in ALS such as 
FUS or TDP-43, RGNEF does not do this by participating in stress granules. Moreover, 
the activation of the RhoA pathway via RGNEF’s DH/PH domain does not appear 
critical for its protection against stress. Instead, RGNEF’s effects seem to involve many 
regions of the protein in both the N-terminal and C-terminal halves. The leucine-rich 
domain of the N-terminal region appears especially important under sorbitol stress where 
its deletion from the full length protein leads to sorbitol susceptibility. Also, instead of 
stress granule formation, RGNEF occasionally colocalizes with staufen-positive transport 
granules under arsenite and sorbitol.  
Based on my results that show RGNEF provides protection against oxidative and osmotic 
stress, we can therefore hypothesize that where RGNEF is sequestered into NCIs within 
ALS spinal motor neurons, the protein’s protetive functions are lost. Moreover, RGNEF 
NCIs often harbor other RNA-binding proteins involved in ALS (Keller et al., 2012). The 
cumulative loss of these proteins (e.g. TDP-43, FUS, RGNEF, etc.) may ultimately cause 
ALS motor neurons to be specifically susceptible to oxidative stress, leading to their 
observed death in the disease couse. Thus, my work provides another piece of evidence 
supporting a hypothesis which could potentially explain the selective death of motor 
neurons in ALS pathogenesis.  
Future experiments building on my work should focus on elucidating the domains and 
interactors of RGNEF that participate in RGNEF’s pathway in stress protection. My 
results suggest that there are domains of importance within the N-terminal region of the 
protein that need to be further studied. Moreover, the leucine rich domain of RGNEF 
suggests protein-protein interactions that may be integral to its function against stress, 
and for this reason should be studied in greater detail. In addition, experiments to 
characterize the biochemical properties of the massively truncated RGNEF mutant 
protein should be performed to see how this mutation may affect RGNEF’s protective 
properties (Droppelmann et al., 2013; Ma et al., 2014). Interestingly, this truncation 
preserves the leucine rich region of RGNEF, once again highlighting this domain’s 
potential importance in cellular function. 
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It should be noted that because experiments were performed using the HEK 293T cell 
line, results obtained in my experiments may differ in humans due to the large difference 
in physiological complexity (homogeneous cell line versus a multicellular organism) 
between the two systems. Therefore, future experimental models should move 
progressively closer to a human model. The progression should move next to examine 
neuronal cell lines such as human cortical neurons or inducible pluripotent stem cells 
differentiated into motor neurons to confirm that our observations do not change within a 
neuronal environment. From there, animal models should be studied so that our 
observations of RGNEF’s protective abilities can be confirmed in a complex 
physiological system. Murine models may prove more difficult to use however as the 
presence of p190RhoGEF within these models means that unexpected interactions may 
occur between the two proteins, especially because the two proteins function differently 
despite being homologues of each other (Droppelmann et al., 2013). 
  
77 
 
Bibliography 
 
Abe, H., Kamai, T., Hayashi, K., Anzai, N., Shirataki, H., Mizuno, T. et al. 
(2014). The Rho-kinase inhibitor HA-1077 suppresses proliferation/migration and 
induces apoptosis of urothelial cancer cells. BMC.Cancer, 14, 412. 
Al-Chalabi, A. & Hardiman, O. (2013). The epidemiology of ALS: a conspiracy 
of genes, environment and time. Nat.Rev.Neurol., 9, 617-628. 
Al-Chalabi, A., Jones, A., Troakes, C., King, A., Al-Sarraj, S., & van den Berg, L. 
H. (2012). The genetics and neuropathology of amyotrophic lateral sclerosis. Acta 
Neuropathol., 124, 339-352. 
Al-Gayyar, M. M., Mysona, B. A., Matragoon, S., Abdelsaid, M. A., El-Azab, M. 
F., Shanab, A. Y. et al. (2013). Diabetes and overexpression of proNGF cause retinal 
neurodegeneration via activation of RhoA pathway. PLoS.One., 8, e54692. 
Alami, N. H., Smith, R. B., Carrasco, M. A., Williams, L. A., Winborn, C. S., 
Han, S. S. et al. (2014). Axonal transport of TDP-43 mRNA granules is impaired by 
ALS-causing mutations. Neuron, 81, 536-543. 
Alkon, D. L., Sun, M. K., & Nelson, T. J. (2007). PKC signaling deficits: a 
mechanistic hypothesis for the origins of Alzheimer's disease. Trends Pharmacol.Sci., 28, 
51-60. 
Anderson, P. & Kedersha, N. (2008). Stress granules: the Tao of RNA triage. 
Trends Biochem.Sci., 33, 141-150. 
78 
 
Anderson, P. & Kedersha, N. (2009). RNA granules: post-transcriptional and 
epigenetic modulators of gene expression. Nat.Rev.Mol.Cell Biol., 10, 430-436. 
Arai, T., Hasegawa, M., Akiyama, H., Ikeda, K., Nonaka, T., Mori, H. et al. 
(2006). TDP-43 is a component of ubiquitin-positive tau-negative inclusions in 
frontotemporal lobar degeneration and amyotrophic lateral sclerosis. 
Biochem.Biophys.Res.Commun., 351, 602-611. 
Arimoto, K., Fukuda, H., Imajoh-Ohmi, S., Saito, H., & Takekawa, M. (2008). 
Formation of stress granules inhibits apoptosis by suppressing stress-responsive MAPK 
pathways. Nat.Cell Biol., 10, 1324-1332. 
Aulas, A., Stabile, S., & Vande Velde, C. (2012). Endogenous TDP-43, but not 
FUS, contributes to stress granule assembly via G3BP. Mol.Neurodegener., 7, 54. 
Banati, R. B., Gehrmann, J., Schubert, P., & Kreutzberg, G. W. (1993). 
Cytotoxicity of microglia. Glia, 7, 111-118. 
Bekenstein, U. & Soreq, H. (2013). Heterogeneous nuclear ribonucleoprotein A1 
in health and neurodegenerative disease: from structural insights to post-transcriptional 
regulatory roles. Mol.Cell Neurosci., 56, 436-446. 
Bergeron, C., Beric-Maskarel, K., Muntasser, S., Weyer, L., Somerville, M. J., & 
Percy, M. E. (1994). Neurofilament light and polyadenylated mRNA levels are decreased 
in amyotrophic lateral sclerosis motor neurons. J.Neuropathol.Exp.Neurol., 53, 221-230. 
79 
 
Blokhuis, A. M., Groen, E. J., Koppers, M., van den Berg, L. H., & Pasterkamp, 
R. J. (2013). Protein aggregation in amyotrophic lateral sclerosis. Acta Neuropathol., 125, 
777-794. 
Brengues, M., Teixeira, D., & Parker, R. (2005). Movement of eukaryotic 
mRNAs between polysomes and cytoplasmic processing bodies. Science, 310, 486-489. 
Brooks, B. R. (1994). El Escorial World Federation of Neurology criteria for the 
diagnosis of amyotrophic lateral sclerosis. Subcommittee on Motor Neuron 
Diseases/Amyotrophic Lateral Sclerosis of the World Federation of Neurology Research 
Group on Neuromuscular Diseases and the El Escorial "Clinical limits of amyotrophic 
lateral sclerosis" workshop contributors. J.Neurol.Sci., 124 Suppl, 96-107. 
Bruijn, L. I., Becher, M. W., Lee, M. K., Anderson, K. L., Jenkins, N. A., 
Copeland, N. G. et al. (1997). ALS-linked SOD1 mutant G85R mediates damage to 
astrocytes and promotes rapidly progressive disease with SOD1-containing inclusions. 
Neuron, 18, 327-338. 
Bruijn, L. I., Houseweart, M. K., Kato, S., Anderson, K. L., Anderson, S. D., 
Ohama, E. et al. (1998). Aggregation and motor neuron toxicity of an ALS-linked SOD1 
mutant independent from wild-type SOD1. Science, 281, 1851-1854. 
Bruijn, L. I., Miller, T. M., & Cleveland, D. W. (2004). Unraveling the 
mechanisms involved in motor neuron degeneration in ALS. Annu.Rev.Neurosci., 27, 
723-749. 
80 
 
Brunelle, J. K. & Letai, A. (2009). Control of mitochondrial apoptosis by the Bcl-
2 family. J.Cell Sci., 122, 437-441. 
Buratti, E., Dork, T., Zuccato, E., Pagani, F., Romano, M., & Baralle, F. E. 
(2001). Nuclear factor TDP-43 and SR proteins promote in vitro and in vivo CFTR exon 
9 skipping. EMBO J., 20, 1774-1784. 
Calini, D., Corrado, L., Del, B. R., Gagliardi, S., Pensato, V., Verde, F. et al. 
(2013). Analysis of hnRNPA1, A2/B1, and A3 genes in patients with amyotrophic lateral 
sclerosis. Neurobiol.Aging, 34, 2695-2. 
Canete-Soler, R., Wu, J., Zhai, J., Shamim, M., & Schlaepfer, W. W. (2001). 
p190RhoGEF Binds to a destabilizing element in the 3' untranslated region of light 
neurofilament subunit mRNA and alters the stability of the transcript. J.Biol.Chem., 276, 
32046-32050. 
Charcot, J. M. & Joffroy, A. (1869). Deux cas d'atrophie musculaire progressive 
avec lesions de la substance grise et des faisceaux antero-lateraux de la moelle epiniere. 
Arch.Physiol.Neurol.Pathol., 2, 744. 
Chaudhuri, K. R., Crump, S., Al-Sarraj, S., Anderson, V., Cavanagh, J., & Leigh, 
P. N. (1995). The validation of El Escorial criteria for the diagnosis of amyotrophic 
lateral sclerosis: a clinicopathological study. J.Neurol.Sci., 129 Suppl, 11-12. 
Chen, H., Qian, K., Du, Z., Cao, J., Petersen, A., Liu, H. et al. (2014). Modeling 
ALS with iPSCs reveals that mutant SOD1 misregulates neurofilament balance in motor 
neurons. Cell Stem Cell, 14, 796-809. 
81 
 
Chen, S., Zhang, X., Song, L., & Le, W. (2012). Autophagy dysregulation in 
amyotrophic lateral sclerosis. Brain Pathol., 22, 110-116. 
Chen, Y. Z., Bennett, C. L., Huynh, H. M., Blair, I. P., Puls, I., Irobi, J. et al. 
(2004). DNA/RNA helicase gene mutations in a form of juvenile amyotrophic lateral 
sclerosis (ALS4). Am.J.Hum.Genet., 74, 1128-1135. 
Chio, A., Logroscino, G., Traynor, B. J., Collins, J., Simeone, J. C., Goldstein, L. 
A. et al. (2013). Global epidemiology of amyotrophic lateral sclerosis: a systematic 
review of the published literature. Neuroepidemiology, 41, 118-130. 
Chio, A., Traynor, B. J., Lombardo, F., Fimognari, M., Calvo, A., Ghiglione, P. et 
al. (2008). Prevalence of SOD1 mutations in the Italian ALS population. Neurology, 70, 
533-537. 
Chuang, C. L., Lu, Y. N., Wang, H. C., & Chang, H. Y. (2014). Genetic 
dissection reveals that Akt is the critical kinase downstream of LRRK2 to phosphorylate 
and inhibit FOXO1, and promotes neuron survival. Hum.Mol.Genet.. 
Collard, J. F., Cote, F., & Julien, J. P. (1995). Defective axonal transport in a 
transgenic mouse model of amyotrophic lateral sclerosis. Nature, 375, 61-64. 
Collins, M., Riascos, D., Kovalik, T., An, J., Krupa, K., Krupa, K. et al. (2012). 
The RNA-binding motif 45 (RBM45) protein accumulates in inclusion bodies in 
amyotrophic lateral sclerosis (ALS) and frontotemporal lobar degeneration with TDP-43 
inclusions (FTLD-TDP) patients. Acta Neuropathol., 124, 717-732. 
82 
 
Corbo, M. & Hays, A. P. (1992). Peripherin and neurofilament protein coexist in 
spinal spheroids of motor neuron disease. J.Neuropathol.Exp.Neurol., 51, 531-537. 
Costa, J., Swash, M., & de Carvalho, M. (2012). Awaji criteria for the diagnosis 
of amyotrophic lateral sclerosis:a systematic review. Arch.Neurol., 69, 1410-1416. 
Cote, F., Collard, J. F., & Julien, J. P. (1993). Progressive neuronopathy in 
transgenic mice expressing the human neurofilament heavy gene: a mouse model of 
amyotrophic lateral sclerosis. Cell, 73, 35-46. 
Couthouis, J., Hart, M. P., Erion, R., King, O. D., Diaz, Z., Nakaya, T. et al. 
(2012). Evaluating the role of the FUS/TLS-related gene EWSR1 in amyotrophic lateral 
sclerosis. Hum.Mol.Genet., 21, 2899-2911. 
Couthouis, J., Hart, M. P., Shorter, J., DeJesus-Hernandez, M., Erion, R., 
Oristano, R. et al. (2011). A yeast functional screen predicts new candidate ALS disease 
genes. Proc.Natl.Acad.Sci.U.S.A, 108, 20881-20890. 
Cox, P. A. & Sacks, O. W. (2002). Cycad neurotoxins, consumption of flying 
foxes, and ALS-PDC disease in Guam. Neurology, 58, 956-959. 
Cui, F., Liu, M., Chen, Y., Huang, X., Cui, L., Fan, D. et al. (2014). 
Epidemiological characteristics of motor neuron disease in Chinese patients. Acta 
Neurol.Scand.. 
83 
 
DeJesus-Hernandez, M., Mackenzie, I. R., Boeve, B. F., Boxer, A. L., Baker, M., 
Rutherford, N. J. et al. (2011). Expanded GGGGCC hexanucleotide repeat in noncoding 
region of C9ORF72 causes chromosome 9p-linked FTD and ALS. Neuron, 72, 245-256. 
Del Re, D. P., Miyamoto, S., & Brown, J. H. (2008). Focal adhesion kinase as a 
RhoA-activable signaling scaffold mediating Akt activation and cardiomyocyte 
protection. J.Biol.Chem., 283, 35622-35629. 
Deng, H. X., Chen, W., Hong, S. T., Boycott, K. M., Gorrie, G. H., Siddique, N. 
et al. (2011). Mutations in UBQLN2 cause dominant X-linked juvenile and adult-onset 
ALS and ALS/dementia. Nature, 477, 211-215. 
Deng, H. X., Zhai, H., Bigio, E. H., Yan, J., Fecto, F., Ajroud, K. et al. (2010). 
FUS-immunoreactive inclusions are a common feature in sporadic and non-SOD1 
familial amyotrophic lateral sclerosis. Ann.Neurol., 67, 739-748. 
Droppelmann, C. A., Campos-Melo, D., Ishtiaq, M., Volkening, K., & Strong, M. 
J. (2014). RNA metabolism in ALS: When normal processes become pathological. 
Amyotroph.Lateral.Scler.Frontotemporal.Degener.. 
Droppelmann, C. A., Keller, B. A., Campos-Melo, D., Volkening, K., & Strong, 
M. J. (2013). Rho guanine nucleotide exchange factor is an NFL mRNA destabilizing 
factor that forms cytoplasmic inclusions in amyotrophic lateral sclerosis. 
Neurobiol.Aging, 34, 248-262. 
Droppelmann, C. A., Wang, J., Campos-Melo, D., Keller, B., Volkening, K., 
Hegele, R. A. et al. (2013). Detection of a novel frameshift mutation and regions with 
84 
 
homozygosis within ARHGEF28 gene in familial amyotrophic lateral sclerosis. 
Amyotroph.Lateral.Scler.Frontotemporal.Degener., 14, 444-451. 
Eisinger-Mathason, T. S., Andrade, J., Groehler, A. L., Clark, D. E., Muratore-
Schroeder, T. L., Pasic, L. et al. (2008). Codependent functions of RSK2 and the 
apoptosis-promoting factor TIA-1 in stress granule assembly and cell survival. Mol.Cell, 
31, 722-736. 
Elden, A. C., Kim, H. J., Hart, M. P., Chen-Plotkin, A. S., Johnson, B. S., Fang, 
X. et al. (2010). Ataxin-2 intermediate-length polyglutamine expansions are associated 
with increased risk for ALS. Nature, 466, 1069-1075. 
Eulalio, A., Behm-Ansmant, I., & Izaurralde, E. (2007). P bodies: at the 
crossroads of post-transcriptional pathways. Nat.Rev.Mol.Cell Biol., 8, 9-22. 
Ferrandon, D., Koch, I., Westhof, E., & Nusslein-Volhard, C. (1997). RNA-RNA 
interaction is required for the formation of specific bicoid mRNA 3' UTR-STAUFEN 
ribonucleoprotein particles. EMBO J., 16, 1751-1758. 
Ferrante, R. J., Browne, S. E., Shinobu, L. A., Bowling, A. C., Baik, M. J., 
MacGarvey, U. et al. (1997). Evidence of increased oxidative damage in both sporadic 
and familial amyotrophic lateral sclerosis. J.Neurochem., 69, 2064-2074. 
Figlewicz, D. A., Krizus, A., Martinoli, M. G., Meininger, V., Dib, M., Rouleau, 
G. A. et al. (1994). Variants of the heavy neurofilament subunit are associated with the 
development of amyotrophic lateral sclerosis. Hum.Mol.Genet., 3, 1757-1761. 
85 
 
Filliben, J. J. & Heckert, A. (2014). Grubbs' Test for Outliers. In J.J.Filliben (Ed.), 
Engineering Statistics Handbook ( National Institute of Standards and Technology. 
Fox, A. H., Lam, Y. W., Leung, A. K., Lyon, C. E., Andersen, J., Mann, M. et al. 
(2002). Paraspeckles: a novel nuclear domain. Curr.Biol., 12, 13-25. 
Fratta, P., Poulter, M., Lashley, T., Rohrer, J. D., Polke, J. M., Beck, J. et al. 
(2013). Homozygosity for the C9orf72 GGGGCC repeat expansion in frontotemporal 
dementia. Acta Neuropathol., 126, 401-409. 
Gama Sosa, M. A., Friedrich, V. L., Jr., DeGasperi, R., Kelley, K., Wen, P. H., 
Senturk, E. et al. (2003). Human midsized neurofilament subunit induces motor neuron 
disease in transgenic mice. Exp.Neurol., 184, 408-419. 
Garruto, R. M. (2006). A commentary on neuronal degeneration and cell death in 
Guam ALS and PD: an evolutionary process of understanding. Curr.Alzheimer Res., 3, 
397-401. 
Garruto, R. M., Yanagihara, R., & Gajdusek, D. C. (1985). Disappearance of 
high-incidence amyotrophic lateral sclerosis and parkinsonism-dementia on Guam. 
Neurology, 35, 193-198. 
Ge, W. W., Wen, W., Strong, W., Leystra-Lantz, C., & Strong, M. J. (2005). 
Mutant copper-zinc superoxide dismutase binds to and destabilizes human low molecular 
weight neurofilament mRNA. J.Biol.Chem., 280, 118-124. 
86 
 
Gebbink, M. F., Kranenburg, O., Poland, M., van Horck, F. P., Houssa, B., & 
Moolenaar, W. H. (1997). Identification of a novel, putative Rho-specific GDP/GTP 
exchange factor and a RhoA-binding protein: control of neuronal morphology. J.Cell 
Biol., 137, 1603-1613. 
Gilks, N., Kedersha, N., Ayodele, M., Shen, L., Stoecklin, G., Dember, L. M. et 
al. (2004). Stress granule assembly is mediated by prion-like aggregation of TIA-1. 
Mol.Biol.Cell, 15, 5383-5398. 
Greenway, M. J., Andersen, P. M., Russ, C., Ennis, S., Cashman, S., Donaghy, C. 
et al. (2006). ANG mutations segregate with familial and 'sporadic' amyotrophic lateral 
sclerosis. Nat.Genet., 38, 411-413. 
Gros-Louis, F., Gaspar, C., & Rouleau, G. A. (2006). Genetics of familial and 
sporadic amyotrophic lateral sclerosis. Biochim.Biophys.Acta, 1762, 956-972. 
Gros-Louis, F., Lariviere, R., Gowing, G., Laurent, S., Camu, W., Bouchard, J. P. 
et al. (2004). A frameshift deletion in peripherin gene associated with amyotrophic lateral 
sclerosis. J.Biol.Chem., 279, 45951-45956. 
Gurney, M. E., Pu, H., Chiu, A. Y., Dal Canto, M. C., Polchow, C. Y., Alexander, 
D. D. et al. (1994). Motor neuron degeneration in mice that express a human Cu,Zn 
superoxide dismutase mutation. Science, 264, 1772-1775. 
Gustafson, E. A. & Wessel, G. M. (2010). DEAD-box helicases: posttranslational 
regulation and function. Biochem.Biophys.Res.Commun., 395, 1-6. 
87 
 
Hanby, M. F., Scott, K. M., Scotton, W., Wijesekera, L., Mole, T., Ellis, C. E. et 
al. (2011). The risk to relatives of patients with sporadic amyotrophic lateral sclerosis. 
Brain, 134, 3454-3457. 
Hart, M. P. & Gitler, A. D. (2012). ALS-associated ataxin 2 polyQ expansions 
enhance stress-induced caspase 3 activation and increase TDP-43 pathological 
modifications. J.Neurosci., 32, 9133-9142. 
He, B. P., Wen, W., & Strong, M. J. (2002). Activated microglia (BV-2) 
facilitation of TNF-alpha-mediated motor neuron death in vitro. J.Neuroimmunol., 128, 
31-38. 
Heath, P. R. & Shaw, P. J. (2002). Update on the glutamatergic neurotransmitter 
system and the role of excitotoxicity in amyotrophic lateral sclerosis. Muscle Nerve, 26, 
438-458. 
Higashi, S., Kabuta, T., Nagai, Y., Tsuchiya, Y., Akiyama, H., & Wada, K. 
(2013). TDP-43 associates with stalled ribosomes and contributes to cell survival during 
cellular stress. J.Neurochem., 126, 288-300. 
Hirano, A., Donnenfeld, H., Sasaki, S., & Nakano, I. (1984). Fine structural 
observations of neurofilamentous changes in amyotrophic lateral sclerosis. 
J.Neuropathol.Exp.Neurol., 43, 461-470. 
Hoskins, J. M., Meynell, G. G., & Sanders, F. K. (1956). A comparison of 
methods for estimating the viable count of a suspension of tumour cells. Exp.Cell Res., 
11, 297-305. 
88 
 
Igaz, L. M., Kwong, L. K., Chen-Plotkin, A., Winton, M. J., Unger, T. L., Xu, Y. 
et al. (2009). Expression of TDP-43 C-terminal Fragments in Vitro Recapitulates 
Pathological Features of TDP-43 Proteinopathies. J.Biol.Chem., 284, 8516-8524. 
Ingelfinger, D., Arndt-Jovin, D. J., Luhrmann, R., & Achsel, T. (2002). The 
human LSm1-7 proteins colocalize with the mRNA-degrading enzymes Dcp1/2 and Xrnl 
in distinct cytoplasmic foci. RNA., 8, 1489-1501. 
Inohara, N., Koseki, T., del, P. L., Hu, Y., Yee, C., Chen, S. et al. (1999). Nod1, 
an Apaf-1-like activator of caspase-9 and nuclear factor-kappaB. J.Biol.Chem., 274, 
14560-14567. 
Kabashi, E. & Durham, H. D. (2006). Failure of protein quality control in 
amyotrophic lateral sclerosis. Biochim.Biophys.Acta, 1762, 1038-1050. 
Kalla, R., Liu, Z., Xu, S., Koppius, A., Imai, Y., Kloss, C. U. et al. (2001). 
Microglia and the early phase of immune surveillance in the axotomized facial motor 
nucleus: impaired microglial activation and lymphocyte recruitment but no effect on 
neuronal survival or axonal regeneration in macrophage-colony stimulating factor-
deficient mice. J.Comp Neurol., 436, 182-201. 
Kao, H. T. & Nevins, J. R. (1983). Transcriptional activation and subsequent 
control of the human heat shock gene during adenovirus infection. Mol.Cell Biol., 3, 
2058-2065. 
Kedersha, N. & Anderson, P. (2007). Mammalian stress granules and processing 
bodies. Methods Enzymol., 431, 61-81. 
89 
 
Kedersha, N., Cho, M. R., Li, W., Yacono, P. W., Chen, S., Gilks, N. et al. 
(2000). Dynamic shuttling of TIA-1 accompanies the recruitment of mRNA to 
mammalian stress granules. J.Cell Biol., 151, 1257-1268. 
Kedersha, N., Ivanov, P., & Anderson, P. (2013). Stress granules and cell 
signaling: more than just a passing phase? Trends Biochem.Sci., 38, 494-506. 
Kedersha, N., Stoecklin, G., Ayodele, M., Yacono, P., Lykke-Andersen, J., 
Fritzler, M. J. et al. (2005). Stress granules and processing bodies are dynamically linked 
sites of mRNP remodeling. J.Cell Biol., 169, 871-884. 
Kedersha, N. L., Gupta, M., Li, W., Miller, I., & Anderson, P. (1999). RNA-
binding proteins TIA-1 and TIAR link the phosphorylation of eIF-2 alpha to the assembly 
of mammalian stress granules. J.Cell Biol., 147, 1431-1442. 
Keller, B. A., Volkening, K., Droppelmann, C. A., Ang, L. C., Rademakers, R., & 
Strong, M. J. (2012). Co-aggregation of RNA binding proteins in ALS spinal motor 
neurons: evidence of a common pathogenic mechanism. Acta Neuropathol., 124, 733-
747. 
Kiebler, M. A., Hemraj, I., Verkade, P., Kohrmann, M., Fortes, P., Marion, R. M. 
et al. (1999). The mammalian staufen protein localizes to the somatodendritic domain of 
cultured hippocampal neurons: implications for its involvement in mRNA transport. 
J.Neurosci., 19, 288-297. 
90 
 
Kieran, D., Sebastia, J., Greenway, M. J., King, M. A., Connaughton, D., 
Concannon, C. G. et al. (2008). Control of motoneuron survival by angiogenin. 
J.Neurosci., 28, 14056-14061. 
Kiernan, M. C., Vucic, S., Cheah, B. C., Turner, M. R., Eisen, A., Hardiman, O. 
et al. (2011). Amyotrophic lateral sclerosis. Lancet, 377, 942-955. 
Kim, H. J., Kim, N. C., Wang, Y. D., Scarborough, E. A., Moore, J., Diaz, Z. et 
al. (2013). Mutations in prion-like domains in hnRNPA2B1 and hnRNPA1 cause 
multisystem proteinopathy and ALS. Nature, 495, 467-473. 
Kim, P. K., Hailey, D. W., Mullen, R. T., & Lippincott-Schwartz, J. (2008). 
Ubiquitin signals autophagic degradation of cytosolic proteins and peroxisomes. 
Proc.Natl.Acad.Sci.U.S.A, 105, 20567-20574. 
Kim, W. J., Back, S. H., Kim, V., Ryu, I., & Jang, S. K. (2005). Sequestration of 
TRAF2 into stress granules interrupts tumor necrosis factor signaling under stress 
conditions. Mol.Cell Biol., 25, 2450-2462. 
Kim, Y. K., Furic, L., Desgroseillers, L., & Maquat, L. E. (2005). Mammalian 
Staufen1 recruits Upf1 to specific mRNA 3'UTRs so as to elicit mRNA decay. Cell, 120, 
195-208. 
King, A. E., Blizzard, C. A., Southam, K. A., Vickers, J. C., & Dickson, T. C. 
(2012). Degeneration of axons in spinal white matter in G93A mSOD1 mouse 
characterized by NFL and alpha-internexin immunoreactivity. Brain Res., 1465, 90-100. 
91 
 
Kishimoto, K., Liu, S., Tsuji, T., Olson, K. A., & Hu, G. F. (2005). Endogenous 
angiogenin in endothelial cells is a general requirement for cell proliferation and 
angiogenesis. Oncogene, 24, 445-456. 
Kobe, B. & Kajava, A. V. (2001). The leucine-rich repeat as a protein recognition 
motif. Curr.Opin.Struct.Biol., 11, 725-732. 
Kreutzberg, G. W. (1996). Microglia: a sensor for pathological events in the CNS. 
Trends Neurosci., 19, 312-318. 
Kwiatkowski, T. J., Jr., Bosco, D. A., Leclerc, A. L., Tamrazian, E., Vanderburg, 
C. R., Russ, C. et al. (2009). Mutations in the FUS/TLS gene on chromosome 16 cause 
familial amyotrophic lateral sclerosis. Science, 323, 1205-1208. 
Lagier-Tourenne, C., Polymenidou, M., Hutt, K. R., Vu, A. Q., Baughn, M., 
Huelga, S. C. et al. (2012). Divergent roles of ALS-linked proteins FUS/TLS and TDP-43 
intersect in processing long pre-mRNAs. Nat.Neurosci., 15, 1488-1497. 
Lee, E. B., Lee, V. M., & Trojanowski, J. Q. (2012). Gains or losses: molecular 
mechanisms of TDP43-mediated neurodegeneration. Nat.Rev.Neurosci., 13, 38-50. 
Lee, M. K. & Cleveland, D. W. (1996). Neuronal intermediate filaments. 
Annu.Rev.Neurosci., 19, 187-217. 
Lee, M. K., Xu, Z., Wong, P. C., & Cleveland, D. W. (1993). Neurofilaments are 
obligate heteropolymers in vivo. J.Cell Biol., 122, 1337-1350. 
92 
 
Lee, Y. B., Chen, H. J., Peres, J. N., Gomez-Deza, J., Attig, J., Stalekar, M. et al. 
(2013). Hexanucleotide repeats in ALS/FTD form length-dependent RNA foci, sequester 
RNA binding proteins, and are neurotoxic. Cell Rep., 5, 1178-1186. 
Leigh, P. N., Whitwell, H., Garofalo, O., Buller, J., Swash, M., Martin, J. E. et al. 
(1991). Ubiquitin-immunoreactive intraneuronal inclusions in amyotrophic lateral 
sclerosis. Morphology, distribution, and specificity. Brain, 114 ( Pt 2), 775-788. 
Levine, J. B., Kong, J., Nadler, M., & Xu, Z. (1999). Astrocytes interact 
intimately with degenerating motor neurons in mouse amyotrophic lateral sclerosis 
(ALS). Glia, 28, 215-224. 
Levine, T. P., Daniels, R. D., Gatta, A. T., Wong, L. H., & Hayes, M. J. (2013). 
The product of C9orf72, a gene strongly implicated in neurodegeneration, is structurally 
related to DENN Rab-GEFs. Bioinformatics., 29, 499-503. 
Li, S. & Hu, G. F. (2012). Emerging role of angiogenin in stress response and cell 
survival under adverse conditions. J.Cell Physiol, 227, 2822-2826. 
Li, Y. R., King, O. D., Shorter, J., & Gitler, A. D. (2013). Stress granules as 
crucibles of ALS pathogenesis. J.Cell Biol., 201, 361-372. 
Lin, H., Zhai, J., & Schlaepfer, W. W. (2005). RNA-binding protein is involved in 
aggregation of light neurofilament protein and is implicated in the pathogenesis of motor 
neuron degeneration. Hum.Mol.Genet., 14, 3643-3659. 
93 
 
Ling, S. C., Polymenidou, M., & Cleveland, D. W. (2013). Converging 
mechanisms in ALS and FTD: disrupted RNA and protein homeostasis. Neuron, 79, 416-
438. 
Liu, X., Lu, M., Tang, L., Zhang, N., Chui, D., & Fan, D. (2013). ATXN2 CAG 
repeat expansions increase the risk for Chinese patients with amyotrophic lateral 
sclerosis. Neurobiol.Aging, 34, 2236-2238. 
Liu-Yesucevitz, L., Bilgutay, A., Zhang, Y. J., Vanderweyde, T., Citro, A., 
Mehta, T. et al. (2010). Tar DNA binding protein-43 (TDP-43) associates with stress 
granules: analysis of cultured cells and pathological brain tissue. PLoS.One., 5, e13250. 
Ludolph, A. C., Bendotti, C., Blaugrund, E., Hengerer, B., Loffler, J. P., Martin, J. 
et al. (2007). Guidelines for the preclinical in vivo evaluation of pharmacological active 
drugs for ALS/MND: report on the 142nd ENMC international workshop. 
Amyotroph.Lateral.Scler., 8, 217-223. 
Ma, Y., Tang, L., Chen, L., Zhang, B., Deng, P., Wang, J. et al. (2014). 
ARHGEF28 gene exon 6/intron 6 junction mutations in Chinese amyotrophic lateral 
sclerosis cohort. Amyotroph.Lateral.Scler.Frontotemporal.Degener., 15, 309-311. 
Mao, Y. S., Sunwoo, H., Zhang, B., & Spector, D. L. (2011). Direct visualization 
of the co-transcriptional assembly of a nuclear body by noncoding RNAs. Nat.Cell Biol., 
13, 95-101. 
Martin, K. C. & Ephrussi, A. (2009). mRNA localization: gene expression in the 
spatial dimension. Cell, 136, 719-730. 
94 
 
Maruyama, H., Morino, H., Ito, H., Izumi, Y., Kato, H., Watanabe, Y. et al. 
(2010). Mutations of optineurin in amyotrophic lateral sclerosis. Nature, 465, 223-226. 
Menzies, F. M., Grierson, A. J., Cookson, M. R., Heath, P. R., Tomkins, J., 
Figlewicz, D. A. et al. (2002). Selective loss of neurofilament expression in Cu/Zn 
superoxide dismutase (SOD1) linked amyotrophic lateral sclerosis. J.Neurochem., 82, 
1118-1128. 
Millecamps, S., Robertson, J., Lariviere, R., Mallet, J., & Julien, J. P. (2006). 
Defective axonal transport of neurofilament proteins in neurons overexpressing 
peripherin. J.Neurochem., 98, 926-938. 
Miller, N. L., Lawson, C., Kleinschmidt, E. G., Tancioni, I., Uryu, S., & 
Schlaepfer, D. D. (2013). A non-canonical role for Rgnef in promoting integrin-
stimulated focal adhesion kinase activation. J.Cell Sci., 126, 5074-5085. 
Miller, R. G., Mitchell, J. D., & Moore, D. H. (2012). Riluzole for amyotrophic 
lateral sclerosis (ALS)/motor neuron disease (MND). Cochrane.Database.Syst.Rev., 3, 
CD001447. 
Moisse, K. & Strong, M. J. (2006). Innate immunity in amyotrophic lateral 
sclerosis. Biochim.Biophys.Acta, 1762, 1083-1093. 
Moisse, K., Volkening, K., Leystra-Lantz, C., Welch, I., Hill, T., & Strong, M. J. 
(2009). Divergent patterns of cytosolic TDP-43 and neuronal progranulin expression 
following axotomy: implications for TDP-43 in the physiological response to neuronal 
injury. Brain Res., 1249, 202-211. 
95 
 
Mutai, H., Toyoshima, Y., Sun, W., Hattori, N., Tanaka, S., & Shiota, K. (2000). 
PAL31, a novel nuclear protein, expressed in the developing brain. 
Biochem.Biophys.Res.Commun., 274, 427-433. 
Nakagawa, S. & Hirose, T. (2012). Paraspeckle nuclear bodies--useful 
uselessness? Cell Mol.Life Sci., 69, 3027-3036. 
Neumann, M., Bentmann, E., Dormann, D., Jawaid, A., DeJesus-Hernandez, M., 
Ansorge, O. et al. (2011). FET proteins TAF15 and EWS are selective markers that 
distinguish FTLD with FUS pathology from amyotrophic lateral sclerosis with FUS 
mutations. Brain, 134, 2595-2609. 
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., 
Chou, T. T. et al. (2006). Ubiquitinated TDP-43 in frontotemporal lobar degeneration and 
amyotrophic lateral sclerosis. Science, 314, 130-133. 
Nguyen, M. D., Lariviere, R. C., & Julien, J. P. (2001). Deregulation of Cdk5 in a 
mouse model of ALS: toxicity alleviated by perikaryal neurofilament inclusions. Neuron, 
30, 135-147. 
Nishimoto, Y., Nakagawa, S., Hirose, T., Okano, H. J., Takao, M., Shibata, S. et 
al. (2013). The long non-coding RNA nuclear-enriched abundant transcript 1_2 induces 
paraspeckle formation in the motor neuron during the early phase of amyotrophic lateral 
sclerosis. Mol.Brain, 6, 31. 
Nodera, H., Izumi, Y., & Kaji, R. (2007). [New diagnostic criteria of ALS (Awaji 
criteria)]. Brain Nerve, 59, 1023-1029. 
96 
 
Okamoto, K., Hirai, S., Amari, M., Watanabe, M., & Sakurai, A. (1993). Bunina 
bodies in amyotrophic lateral sclerosis immunostained with rabbit anti-cystatin C serum. 
Neurosci.Lett., 162, 125-128. 
Ono, Y., Fujii, T., Igarashi, K., Kuno, T., Tanaka, C., Kikkawa, U. et al. (1989). 
Phorbol ester binding to protein kinase C requires a cysteine-rich zinc-finger-like 
sequence. Proc.Natl.Acad.Sci.U.S.A, 86, 4868-4871. 
Oosthuyse, B., Moons, L., Storkebaum, E., Beck, H., Nuyens, D., Brusselmans, 
K. et al. (2001). Deletion of the hypoxia-response element in the vascular endothelial 
growth factor promoter causes motor neuron degeneration. Nat.Genet., 28, 131-138. 
Ou, S. H., Wu, F., Harrich, D., Garcia-Martinez, L. F., & Gaynor, R. B. (1995). 
Cloning and characterization of a novel cellular protein, TDP-43, that binds to human 
immunodeficiency virus type 1 TAR DNA sequence motifs. J.Virol., 69, 3584-3596. 
Paisan-Ruiz, C., Jain, S., Evans, E. W., Gilks, W. P., Simon, J., van der Brug, M. 
et al. (2004). Cloning of the gene containing mutations that cause PARK8-linked 
Parkinson's disease. Neuron, 44, 595-600. 
Pankiv, S., Clausen, T. H., Lamark, T., Brech, A., Bruun, J. A., Outzen, H. et al. 
(2007). p62/SQSTM1 binds directly to Atg8/LC3 to facilitate degradation of 
ubiquitinated protein aggregates by autophagy. J.Biol.Chem., 282, 24131-24145. 
Parker, R. & Sheth, U. (2007). P bodies and the control of mRNA translation and 
degradation. Mol.Cell, 25, 635-646. 
97 
 
Pasinelli, P., Belford, M. E., Lennon, N., Bacskai, B. J., Hyman, B. T., Trotti, D. 
et al. (2004). Amyotrophic lateral sclerosis-associated SOD1 mutant proteins bind and 
aggregate with Bcl-2 in spinal cord mitochondria. Neuron, 43, 19-30. 
Piao, Y. S., Wakabayashi, K., Kakita, A., Yamada, M., Hayashi, S., Morita, T. et 
al. (2003). Neuropathology with clinical correlations of sporadic amyotrophic lateral 
sclerosis: 102 autopsy cases examined between 1962 and 2000. Brain Pathol., 13, 10-22. 
Plato, C. C., Garruto, R. M., Galasko, D., Craig, U. K., Plato, M., Gamst, A. et al. 
(2003). Amyotrophic lateral sclerosis and parkinsonism-dementia complex of Guam: 
changing incidence rates during the past 60 years. Am.J.Epidemiol., 157, 149-157. 
Puls, I., Jonnakuty, C., LaMonte, B. H., Holzbaur, E. L., Tokito, M., Mann, E. et 
al. (2003). Mutant dynactin in motor neuron disease. Nat.Genet., 33, 455-456. 
Purves, D., Augustine, G. J., Fitzpatrick, D., Katz, L. C., LaMantia, A., 
McNamara, J. O. et al. (2001). Neuroscience. Sunderland (MA): Sinauer Associates. 
Raivich, G. (2005). Like cops on the beat: the active role of resting microglia. 
Trends Neurosci., 28, 571-573. 
Raoul, C., Estevez, A. G., Nishimune, H., Cleveland, D. W., deLapeyriere, O., 
Henderson, C. E. et al. (2002). Motoneuron death triggered by a specific pathway 
downstream of Fas. potentiation by ALS-linked SOD1 mutations. Neuron, 35, 1067-
1083. 
98 
 
Renton, A. E., Chio, A., & Traynor, B. J. (2014). State of play in amyotrophic 
lateral sclerosis genetics. Nat.Neurosci., 17, 17-23. 
Renton, A. E., Majounie, E., Waite, A., Simon-Sanchez, J., Rollinson, S., Gibbs, 
J. R. et al. (2011). A hexanucleotide repeat expansion in C9ORF72 is the cause of 
chromosome 9p21-linked ALS-FTD. Neuron, 72, 257-268. 
Rico, B., Beggs, H. E., Schahin-Reed, D., Kimes, N., Schmidt, A., & Reichardt, 
L. F. (2004). Control of axonal branching and synapse formation by focal adhesion 
kinase. Nat.Neurosci., 7, 1059-1069. 
Rosen, D. R., Siddique, T., Patterson, D., Figlewicz, D. A., Sapp, P., Hentati, A. 
et al. (1993). Mutations in Cu/Zn superoxide dismutase gene are associated with familial 
amyotrophic lateral sclerosis. Nature, 362, 59-62. 
Rothstein, J. D., Martin, L. J., & Kuncl, R. W. (1992). Decreased glutamate 
transport by the brain and spinal cord in amyotrophic lateral sclerosis. N.Engl.J.Med., 
326, 1464-1468. 
Rothstein, J. D., van Kammen, M., Levey, A. I., Martin, L. J., & Kuncl, R. W. 
(1995). Selective loss of glial glutamate transporter GLT-1 in amyotrophic lateral 
sclerosis. Ann.Neurol., 38, 73-84. 
Roussel, B. D., Kruppa, A. J., Miranda, E., Crowther, D. C., Lomas, D. A., & 
Marciniak, S. J. (2013). Endoplasmic reticulum dysfunction in neurological disease. 
Lancet Neurol., 12, 105-118. 
99 
 
Rowland, L. P. & Shneider, N. A. (2001). Amyotrophic lateral sclerosis. 
N.Engl.J.Med., 344, 1688-1700. 
Sama, R. R., Ward, C. L., Kaushansky, L. J., Lemay, N., Ishigaki, S., Urano, F. et 
al. (2013). FUS/TLS assembles into stress granules and is a prosurvival factor during 
hyperosmolar stress. J.Cell Physiol, 228, 2222-2231. 
Sanelli, T. & Strong, M. J. (2007). Loss of nitric oxide-mediated down-regulation 
of NMDA receptors in neurofilament aggregate-bearing motor neurons in vitro: 
implications for motor neuron disease. Free Radic.Biol.Med., 42, 143-151. 
Sanelli, T. R., Sopper, M. M., & Strong, M. J. (2004). Sequestration of nNOS in 
neurofilamentous aggregate bearing neurons in vitro leads to enhanced NMDA-mediated 
calcium influx. Brain Res., 1004, 8-17. 
Sasaki, S. & Maruyama, S. (1992). Increase in diameter of the axonal initial 
segment is an early change in amyotrophic lateral sclerosis. J.Neurol.Sci., 110, 114-120. 
Scotton, W. J., Scott, K. M., Moore, D. H., Almedom, L., Wijesekera, L. C., 
Janssen, A. et al. (2012). Prognostic categories for amyotrophic lateral sclerosis. 
Amyotroph.Lateral.Scler., 13, 502-508. 
Shaw, G., Morse, S., Ararat, M., & Graham, F. L. (2002). Preferential 
transformation of human neuronal cells by human adenoviruses and the origin of HEK 
293 cells. FASEB J., 16, 869-871. 
100 
 
Shelkovnikova, T. A., Robinson, H. K., Troakes, C., Ninkina, N., & Buchman, V. 
L. (2014). Compromised paraspeckle formation as a pathogenic factor in FUSopathies. 
Hum.Mol.Genet., 23, 2298-2312. 
Shibata, N., Nagai, R., Uchida, K., Horiuchi, S., Yamada, S., Hirano, A. et al. 
(2001). Morphological evidence for lipid peroxidation and protein glycoxidation in spinal 
cords from sporadic amyotrophic lateral sclerosis patients. Brain Res., 917, 97-104. 
Simpson, E. P., Yen, A. A., & Appel, S. H. (2003). Oxidative Stress: a common 
denominator in the pathogenesis of amyotrophic lateral sclerosis. Curr.Opin.Rheumatol., 
15, 730-736. 
Slater, T. F., Sawyer, B., & Straeuli, U. (1963). Studies on succinate-tetrazolium 
reductase systems. III. Points of coupling of four different tetrazolium salts. 
Biochim.Biophys.Acta, 77, 383-393. 
Sreedharan, J., Blair, I. P., Tripathi, V. B., Hu, X., Vance, C., Rogelj, B. et al. 
(2008). TDP-43 mutations in familial and sporadic amyotrophic lateral sclerosis. Science, 
319, 1668-1672. 
Steele, J. C. & McGeer, P. L. (2008). The ALS/PDC syndrome of Guam and the 
cycad hypothesis. Neurology, 70, 1984-1990. 
Stenmark, H. (2009). Rab GTPases as coordinators of vesicle traffic. 
Nat.Rev.Mol.Cell Biol., 10, 513-525. 
101 
 
Stepto, A., Gallo, J. M., Shaw, C. E., & Hirth, F. (2014). Modelling C9ORF72 
hexanucleotide repeat expansion in amyotrophic lateral sclerosis and frontotemporal 
dementia. Acta Neuropathol., 127, 377-389. 
Strong, M. J. (2001). Progress in clinical neurosciences: the evidence for ALS as 
a multisystems disorder of limited phenotypic expression. Can.J.Neurol.Sci., 28, 283-
298. 
Strong, M. J. (2010). The evidence for altered RNA metabolism in amyotrophic 
lateral sclerosis (ALS). J.Neurol.Sci., 288, 1-12. 
Strong, M. J., Kesavapany, S., & Pant, H. C. (2005). The pathobiology of 
amyotrophic lateral sclerosis: a proteinopathy? J.Neuropathol.Exp.Neurol., 64, 649-664. 
Strong, M. J., Volkening, K., Hammond, R., Yang, W., Strong, W., Leystra-
Lantz, C. et al. (2007). TDP43 is a human low molecular weight neurofilament (hNFL) 
mRNA-binding protein. Mol.Cell Neurosci., 35, 320-327. 
Subramanian, V., Crabtree, B., & Acharya, K. R. (2008). Human angiogenin is a 
neuroprotective factor and amyotrophic lateral sclerosis associated angiogenin variants 
affect neurite extension/pathfinding and survival of motor neurons. Hum.Mol.Genet., 17, 
130-149. 
Szaro, B. G. & Strong, M. J. (2010). Post-transcriptional control of 
neurofilaments: New roles in development, regeneration and neurodegenerative disease. 
Trends Neurosci., 33, 27-37. 
102 
 
Tacconi, M. T. (1998). Neuronal death: is there a role for astrocytes? 
Neurochem.Res., 23, 759-765. 
Tan, A. Y. & Manley, J. L. (2009). The TET family of proteins: functions and 
roles in disease. J.Mol.Cell Biol., 1, 82-92. 
Tanner, N. K. & Linder, P. (2001). DExD/H box RNA helicases: from generic 
motors to specific dissociation functions. Mol.Cell, 8, 251-262. 
Tosar, L. J., Thomas, M. G., Baez, M. V., Ibanez, I., Chernomoretz, A., & 
Boccaccio, G. L. (2012). Staufen: from embryo polarity to cellular stress and 
neurodegeneration. Front Biosci.(Schol.Ed), 4, 432-452. 
Tourriere, H., Chebli, K., Zekri, L., Courselaud, B., Blanchard, J. M., Bertrand, E. 
et al. (2003). The RasGAP-associated endoribonuclease G3BP assembles stress granules. 
J.Cell Biol., 160, 823-831. 
Troost, D., van den Oord, J. J., & Vianney de Jong, J. M. (1990). 
Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic 
lateral sclerosis. Neuropathol.Appl.Neurobiol., 16, 401-410. 
van Damme, P., Bogaert, E., Dewil, M., Hersmus, N., Kiraly, D., Scheveneels, W. 
et al. (2007). Astrocytes regulate GluR2 expression in motor neurons and their 
vulnerability to excitotoxicity. Proc.Natl.Acad.Sci.U.S.A, 104, 14825-14830. 
van Horck, F. P., Ahmadian, M. R., Haeusler, L. C., Moolenaar, W. H., & 
Kranenburg, O. (2001). Characterization of p190RhoGEF, a RhoA-specific guanine 
103 
 
nucleotide exchange factor that interacts with microtubules. J.Biol.Chem., 276, 4948-
4956. 
Volkening, K., Leystra-Lantz, C., & Strong, M. J. (2010). Human low molecular 
weight neurofilament (NFL) mRNA interacts with a predicted p190RhoGEF homologue 
(RGNEF) in humans. Amyotroph.Lateral.Scler., 11, 97-103. 
Volkening, K., Leystra-Lantz, C., Yang, W., Jaffee, H., & Strong, M. J. (2009). 
Tar DNA binding protein of 43 kDa (TDP-43), 14-3-3 proteins and copper/zinc 
superoxide dismutase (SOD1) interact to modulate NFL mRNA stability. Implications for 
altered RNA processing in amyotrophic lateral sclerosis (ALS). Brain Res., 1305, 168-
182. 
Williamson, T. L. & Cleveland, D. W. (1999). Slowing of axonal transport is a 
very early event in the toxicity of ALS-linked SOD1 mutants to motor neurons. 
Nat.Neurosci., 2, 50-56. 
Wolozin, B. (2012). Regulated protein aggregation: stress granules and 
neurodegeneration. Mol.Neurodegener., 7, 56. 
Wong, N. K., He, B. P., & Strong, M. J. (2000). Characterization of neuronal 
intermediate filament protein expression in cervical spinal motor neurons in sporadic 
amyotrophic lateral sclerosis (ALS). J.Neuropathol.Exp.Neurol., 59, 972-982. 
Wu, D., Yu, W., Kishikawa, H., Folkerth, R. D., Iafrate, A. J., Shen, Y. et al. 
(2007). Angiogenin loss-of-function mutations in amyotrophic lateral sclerosis. 
Ann.Neurol., 62, 609-617. 
104 
 
Wu, J., Zhai, J., Lin, H., Nie, Z., Ge, W. W., Garcia-Bermejo, L. et al. (2003). 
Cytoplasmic retention sites in p190RhoGEF confer anti-apoptotic activity to an EGFP-
tagged protein. Brain Res.Mol.Brain Res., 117, 27-38. 
Xiao, S., McLean, J., & Robertson, J. (2006). Neuronal intermediate filaments 
and ALS: a new look at an old question. Biochim.Biophys.Acta, 1762, 1001-1012. 
Yuan, A., Rao, M. V., Sasaki, T., Chen, Y., Kumar, A., Veeranna et al. (2006). 
Alpha-internexin is structurally and functionally associated with the neurofilament triplet 
proteins in the mature CNS. J.Neurosci., 26, 10006-10019. 
Zhai, J., Lin, H., Nie, Z., Wu, J., Canete-Soler, R., Schlaepfer, W. W. et al. 
(2003). Direct interaction of focal adhesion kinase with p190RhoGEF. J.Biol.Chem., 278, 
24865-24873. 
Zheng, Y. (2001). Dbl family guanine nucleotide exchange factors. Trends 
Biochem.Sci., 26, 724-732. 
Zimprich, A., Biskup, S., Leitner, P., Lichtner, P., Farrer, M., Lincoln, S. et al. 
(2004). Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic 
pathology. Neuron, 44, 601-607. 
Zu, T., Liu, Y., Banez-Coronel, M., Reid, T., Pletnikova, O., Lewis, J. et al. 
(2013). RAN proteins and RNA foci from antisense transcripts in C9ORF72 ALS and 
frontotemporal dementia. Proc.Natl.Acad.Sci.U.S.A, 110, E4968-E4977. 
 
  
105 
 
Curriculum Vitae 
Kevin Cheung 
 
 
UNIVERSITY EDUCATION BACKGROUND 
 
2012-2014 Master of Science Candidate, Pathology 
  University of Western Ontario, London, Ontario 
Title: “The Role Of The RNA-Binding Protein Rho Guanine Nucleotide 
Exchange Factor In The Cellular Stress Response” 
Supervisor: Dr. Michael J. Strong 
 
2008-2012 Honours Bachelor of Medical Sciences, Pathology and Toxicology 
  University of Western Ontario, London, Ontario 
   
HONORS, SCHOLARSHIPS AND AWARDS DURING UNIVERSITY 
 
2012-2014 Western Graduate Research Scholarship 
 Awarded through a nomination by the full-time student’s graduate 
program 
 
2013  Second Place Poster Award, Fourth International Research Workshop on 
  Frontotemporal Dementia in ALS 
 Awarded to the poster presentation of “Rho Guanine Nucleotide 
Exchange Factor (RGNEF) Affects the Survival of HEK293T Cells 
Exposed to a Variety of Stressors” based on the decision of a panel of 
judges 
 
2009-2012 Dean’s Honour List 
 For outstanding academic achievement while maintaining a full course 
load 
 
2009  Western In-course Scholarship 
 Awarded through faculty nomination to a student based on their 
academic merit 
 
2008  Western Scholarship of Excellence 
 For achieving an average grade of over 90% in the final year of 
secondary school 
 
 
 
 
  
106 
 
RESEARCH EXPERIENCE 
 
2012-present Research-based Master’s Thesis, Department of Pathology, Western 
University 
  Supervisor: Dr. Michael J. Strong  
 Characterized the protective effect of RGNEF protein (implicated in 
amyotrophic lateral sclerosis) on the survival of stressed cells 
 Cultured and transfected several different cell types: HEK293T, Swiss 
3T3, Neuro2A 
 Western blot and densitometry to analyze changes in protein levels 
 Fluorescence immunocytochemistry and confocal microscopy to 
visualize protein localizations and interactions within cells 
 MTT viability assay to examine the protective effect of RGNEF for 
cells 
 Molecular biology techniques including cloning and PCR to generate 
different gene constructs of RGNEF for study in eukaryotic cells 
 Presented results on a regular basis in formal and informal settings 
 
2012 Summer Research Student, Ivey Eye Institute, St. Joseph`s Hospital, 
London, Ontario 
Supervisor: Dr. Cindy Hutnik 
 Investigated the effects of glaucoma medications on ocular surface 
disease  and the potential therapeutic effects of amniotic membrane 
extract on the ocular surface 
 Imaged cell cultures using brightfield microscopy  
 Obtained clinical data and ocular surface samples from patients  
 Cryostat frozen sectioning used to obtain slides for analysis by 
fluorescence immunocytochemistry under confocal microscopy 
 Performed statistical analysis of data 
 Presented and discussed findings with colleagues in weekly lab 
meetings 
 
2011-2012 Fourth-Year Undergraduate Honours Thesis Project, Department of 
Pathology, Western University 
Supervisor: Dr. Stephen Karlik 
 Investigated the angiogenic factors involved in the pathogenesis of 
demyelinated spinal cord lesions in multiple sclerosis 
 Cut formalin-fixed, paraffin-embedded tissue samples and analyzed 
tissue using hematoxylin & eosin and immunohistochemistry methods 
 Scored slides based on appearance of staining as observed through 
light microscopy 
 Performed statistical analysis of data 
 Wrote and presented proposals to peers within the department 
 Presented findings in a graded podium presentation to departmental 
peers 
107 
 
 
PUBLICATIONS, PRESENTATIONS AND ABSTRACTS 
 
2014 Poster and Podium Presentation, Robarts Research Retreat 2014, 
Western University, London, Ontario  
 TITLE: The role of Rho Guanine Nucleotide Exchange Factor, an 
aggregate forming RNA-binding protein in amyotrophic lateral 
sclerosis, in the cellular stress response 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Michael J. Strong 
 
2014 Poster Presentation, 2014 Annual Meeting of the Southern Ontario 
Neuroscience Association, Society for Neuroscience, London, Ontario 
 TITLE: The role of Rho Guanine Nucleotide Exchange Factor, a novel 
RNA-binding protein discovered in amyotrophic lateral sclerosis, in 
the cellular stress response 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Michael J. Strong 
 
2014 Poster Presentation, 2014 Annual Pathology Research Day, Schulich 
School of Medicine and Dentistry, Western University, London, Ontario 
 TITLE: The role of Rho Guanine Nucleotide Exchange Factor, an 
RNA-binding protein discovered in amyotrophic lateral sclerosis, in 
stress response 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Michael J. Strong 
 
2014 Poster Presentation, London Health Research Day 2014, London, 
Ontario 
 TITLE: The role of Rho Guanine Nucleotide Exchange Factor, a novel 
RNA-binding protein discovered in amyotrophic lateral sclerosis, in 
the cellular stress response 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Michael J. Strong 
 
2013 Poster Presentation (abstract publication), 43rd Annual Meeting of the 
Society for Neuroscience, San Diego, California 
 TITLE: Cytoprotective effect of Rho guanine nucleotide exchange 
factor (RGNEF) 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Ian Cameron, Stephen H. Pasternak, Michael J. Strong 
 
2013 Poster Presentation (abstract publication), ARVO Annual Meeting 
2013, Orlando, Florida 
 TITLE: The Effects of Amniotic Membrane Extract on Primary 
Human Corneal Epithelial Cells 
108 
 
 AUTHORS: David V.Dudok, Kevin Cheung, Hong Liu, Luca 
Vedovelli, Emiliano Ghinelli, Ken Kenyon, Sunil Parapuram, Cindy 
M. Hutnik 
 
2013 Poster Presentation, 2013 Annual Pathology Research Day, Schulich 
School of Medicine and Dentistry, Western University, London, Ontario 
 TITLE: RGNEF does not co-localize with stress granules, but may 
increase cell survival under various conditions of cellular stress 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Michael J. Strong 
 
2013 Poster and Podium Presentation, Fourth International Research 
Workshop on Frontotemporal Dementia in ALS, London, Ontario 
 TITLE: Rho guanine nucleotide exchange factor (RGNEF) affects the 
survival of HEK293T cells exposed to a variety of stressors 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Michael J. Strong 
 
2013 Poster Presentation, ALS Canada Research Forum 2013, Toronto, 
Ontario 
 TITLE: Rho guanine nucleotide exchange factor (RGNEF) affects the 
survival of HEK293T cells exposed to a variety of stressors 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Michael J. Strong 
 
2013 Poster Presentation, London Health Research Day 2013, London, 
Ontario 
 TITLE: RGNEF does not co-localize to stress granules in amyotrophic 
lateral sclerosis, but may increase cell survival under stress 
 AUTHORS: Kevin Cheung, Cristian Droppelmann, Kathryn 
Volkening, Michael J. Strong 
 
2012 Podium Presentation, Western Undergraduate Research Journal’s 
Research Forum, Western University 
 TITLE: Immunohistochemical analysis of protein markers in mice 
with experimental allergic encephalomyelitis induced by MOG(35-55) 
peptide and in humans with multiple sclerosis 
 AUTHORS: Kevin Cheung, Wendy Roscoe, Robin Smith, Stephen 
Karlik 
 
2012  Poster Presentation, Annual Pathology and Toxicology Research Day,  
  Western University 
 TITLE: Comparison of various protein factors in mice with 
Experimental Allergic Encephalomyelitis and in humans with Multiple 
Sclerosis 
109 
 
 AUTHORS: Kevin Cheung, Wendy Roscoe, Robin Smith, Stephen 
Karlik 
 
TEACHING EXPERIENCE DURING UNIVERSITY 
 
2014 Jan-Apr Graduate Teaching Assistant, Department of Pathology, Western 
University 
  Course Taught: Environmental Pathology (PATH 4400B) 
 Grading assignments and tests according to rubric outlined by 
instructor 
 Answering student questions about both course material and grading  
 Proctoring course midterms and exams 
 Providing professor with feedback about student performance on tests 
and assignments, and discussing rubrics prior to grading assignments 
 
 
